Entero Therapeutics (ENTO) 10-Q/A 16 Nov 21 2021 Q3 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Document Information [Line Items]
Entity Central Index Key	0001604191
Entity Registrant Name	First Wave BioPharma, Inc.
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-37853
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4993860
Entity Address, Address Line One	777 Yamato Road, Suite 502
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	589-7020
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	FWBI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,460,848
Amendment Description	First Wave BioPharma, Inc. (the “Company”) is filing this amendment (the “Amendment”) to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Quarterly Report”) to furnish the Interactive Data files as Exhibit 101. For the convenience of the reader, this Amendment refiles in its entirety the Quarterly Report. Additionally, this filing includes updated CEO and CFO certifications filed as Exhibits 31.1, 31.2, 32.1, 32.2. No other changes have been made to the original filing.

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 7,210,645	$ 6,062,141
Other receivables	0	551,489
Prepaid expenses	291,844	1,256,154
Total Current Assets	7,502,489	7,869,784
Property, equipment, and leasehold improvements, net	80,387	18,329
Other Assets:
Patents, net	2,483,875	2,879,536
Goodwill	1,944,742	2,054,048
Operating lease right-of-use assets	368,502	74,238
Deposits	44,034	27,920
Total Other Assets	4,841,153	5,035,742
Total Assets	12,424,029	12,923,855
Current Liabilities:
Accounts payable and accrued expenses	18,582,906	1,685,603
Payable related to license agreement	0	13,250,000
Accrued dividend payable	349,131	0
Note payable	0	552,405
Other current liabilities	166,291	57,417
Total Current Liabilities	19,098,328	15,545,425
Other liabilities	295,689	19,123
Total Liabilities	19,394,017	15,564,548
Stockholders' Equity:
Common stock - Par value $0.0001 per share; 25,000,000 shares authorized; 11,115,228 and 3,115,031 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.	1,112	312
Additional paid-in capital	137,027,567	93,837,739
Accumulated deficit	(142,731,560)	(95,366,198)
Accumulated other comprehensive loss	(1,267,107)	(1,112,546)
Total Stockholders' Equity	(6,969,988)	(2,640,693)
Total Liabilities and Stockholders' Equity	12,424,029	12,923,855
Series B Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	0	0
Series C Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	$ 0	$ 0

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Feb. 28, 2021	Feb. 23, 2021	Jan. 05, 2021	Dec. 31, 2020	Jul. 16, 2020	Dec. 31, 2019	Dec. 20, 2019	Feb. 24, 2019
Common stock, par value (in dollars per share)	$ 0.0001				$ 0.0001			$ 0.0001
Common stock, shares authorized (in shares)	25,000,000	250,000,000			25,000,000		150,000,000	15,000,000	25,000,000
Common stock, shares issued (in shares)	11,115,228				3,115,031
Common stock, shares outstanding (in shares)	11,115,228				3,115,031
Preferred stock, par value (in dollars per share)	$ 0.0001							$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000							10,000,000
Preferred stock, shares issued (in shares)	676.05
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001				$ 0.0001
Preferred stock, shares authorized (in shares)	5,194.81				5,194.81	5,194.805195
Preferred stock, shares issued (in shares)	676.05				2,773.6
Preferred stock, shares outstanding (in shares)	676.05				2,773.6
Series C Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001				$ 0.0001
Preferred stock, shares authorized (in shares)	57,000			75,000	57,000
Preferred stock, shares issued (in shares)	0				0
Preferred stock, shares outstanding (in shares)	0		334.46		0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development expenses	$ 24,378,318	$ 1,795,684	$ 32,542,143	$ 4,438,229
General and administrative expenses	6,021,160	1,916,250	15,347,764	4,595,860
Total operating expenses	30,399,478	3,711,934	47,889,907	9,034,089
Loss from operations	(30,399,478)	(3,711,934)	(47,889,907)	(9,034,089)
Other income (expenses):
Interest expense	(742)	(1,203,404)	(8,840)	(5,838,417)
Gain on settlement	0	211,430	0	211,430
Loss on debt extinguishment	0	(609,998)	0	(609,998)
Other income	(568)	0	1,032	0
Change in fair value of liability	0	0	532,353	0
Total other income (expenses)	(1,310)	(1,601,972)	524,545	(6,236,985)
Net loss	(30,400,788)	(5,313,906)	(47,365,362)	(15,271,074)
Other comprehensive loss:
Foreign currency translation adjustment	(41,604)	61,232	(154,561)	55,007
Total comprehensive loss	(30,442,392)	(5,252,674)	(47,519,923)	(15,216,067)
Net loss	(30,400,788)	(5,313,906)	(47,365,362)	(15,271,074)
Deemed dividend on preferred stock	0	(8,155,212)	(4,507,125)	(8,155,212)
Deemed dividend on preferred stock exchanges	0	0	(21,008,253)	0
Preferred stock dividends	(118,089)	0	(349,132)	0
Net loss applicable to common shareholders	$ (30,518,877)	$ (13,469,118)	$ (73,229,872)	$ (23,426,286)
Basic and diluted weighted average shares outstanding (in shares)	9,342,357	2,851,883	7,593,545	2,782,823
Loss per share - basic and diluted (in dollars per share)	$ (3.27)	$ (4.72)	$ (9.64)	$ (8.42)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Series C Preferred Stock and Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series C Preferred Stock and Warrants [Member]Additional Paid-in Capital [Member]	Series C Preferred Stock and Warrants [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Common Stock [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Additional Paid-in Capital [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]	Common Stock Offering [Member]Common Stock [Member]	Common Stock Offering [Member]Additional Paid-in Capital [Member]	Common Stock Offering [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Common Stock [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]Retained Earnings [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Warrants Issued in Connection With Exchange of Series B Preferred Stock [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Promissory Notes Converted into Series B Preferred Stock and Warrants [Member]Additional Paid-in Capital [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Promissory Notes Converted into Series B Preferred Stock and Warrants [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Common Stock [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]Retained Earnings [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]AOCI Attributable to Parent [Member]	Warrants Issued In Promissory Note Exchanged for Series B Convertible Preferred Stock [Member]	Warrants Issued in Association With Convertible Debt [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Warrants Issued in Association With Convertible Debt [Member]Common Stock [Member]	Warrants Issued in Association With Convertible Debt [Member]Additional Paid-in Capital [Member]	Warrants Issued in Association With Convertible Debt [Member]Retained Earnings [Member]	Warrants Issued in Association With Convertible Debt [Member]AOCI Attributable to Parent [Member]	Warrants Issued in Association With Convertible Debt [Member]	Conversion Feature of Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion Feature of Series B Preferred Stock [Member]Common Stock [Member]	Conversion Feature of Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Conversion Feature of Series B Preferred Stock [Member]Retained Earnings [Member]	Conversion Feature of Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Conversion Feature of Series B Preferred Stock [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Common Stock [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]Retained Earnings [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Series B Preferred Stock to Series C Preferred Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]Common Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]Retained Earnings [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Common Stock [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Retained Earnings [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]	Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Common Stock [Member]	Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]Retained Earnings [Member]	Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Common Stock Issued for Accrued Dividends Upon Conversion of Series B Preferred Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]Common Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]Retained Earnings [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]	Common Stock Issued to Settle Accounts Payable [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock Issued to Settle Accounts Payable [Member]Common Stock [Member]	Common Stock Issued to Settle Accounts Payable [Member]Additional Paid-in Capital [Member]	Common Stock Issued to Settle Accounts Payable [Member]Retained Earnings [Member]	Common Stock Issued to Settle Accounts Payable [Member]AOCI Attributable to Parent [Member]	Common Stock Issued to Settle Accounts Payable [Member]	Series B Preferred Stock Converted into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series B Preferred Stock Converted into Common Stock [Member]Common Stock [Member]	Series B Preferred Stock Converted into Common Stock [Member]Additional Paid-in Capital [Member]	Series B Preferred Stock Converted into Common Stock [Member]Retained Earnings [Member]	Series B Preferred Stock Converted into Common Stock [Member]AOCI Attributable to Parent [Member]	Series B Preferred Stock Converted into Common Stock [Member]	Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Common Stock [Member]	Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]Retained Earnings [Member]	Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Common Stock for Accrued Dividends Upon Series B Preferred Stock [Member]	Dividend on Series C Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Dividend on Series C Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Dividend on Series C Preferred Stock [Member]Common Stock [Member]	Dividend on Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Dividend on Series C Preferred Stock [Member]Retained Earnings [Member]	Dividend on Series C Preferred Stock [Member]AOCI Attributable to Parent [Member]	Dividend on Series C Preferred Stock [Member]	Dividend on Series B Preferred Stock [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Dividend on Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Dividend on Series B Preferred Stock [Member]Common Stock [Member]	Dividend on Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Dividend on Series B Preferred Stock [Member]Retained Earnings [Member]	Dividend on Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Dividend on Series B Preferred Stock [Member]	Dividends on Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Dividends on Series B Preferred Stock [Member]Common Stock [Member]	Dividends on Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Dividends on Series B Preferred Stock [Member]Retained Earnings [Member]	Dividends on Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Dividends on Series B Preferred Stock [Member]	Preferred Stock Dividend [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock Dividend [Member]Common Stock [Member]	Preferred Stock Dividend [Member]Additional Paid-in Capital [Member]	Preferred Stock Dividend [Member]Retained Earnings [Member]	Preferred Stock Dividend [Member]AOCI Attributable to Parent [Member]	Preferred Stock Dividend [Member]	Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Common Stock [Member]	Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]Retained Earnings [Member]	Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Dividend Related to Exchange of Promissory Notes Into Series B Preferred Stock [Member]	Conversion Feature on Convertible Debt Issuances [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion Feature on Convertible Debt Issuances [Member]Common Stock [Member]	Conversion Feature on Convertible Debt Issuances [Member]Additional Paid-in Capital [Member]	Conversion Feature on Convertible Debt Issuances [Member]Retained Earnings [Member]	Conversion Feature on Convertible Debt Issuances [Member]AOCI Attributable to Parent [Member]	Conversion Feature on Convertible Debt Issuances [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2019																																																																																																																															0	2,680,052
Balance at Dec. 31, 2019																																																																																																																															$ 0	$ 268	$ 68,578,263	$ (62,694,732)	$ (1,266,555)	$ 4,617,244
Issuance of stock and warrants for cash, net of offering costs (in shares)																																																																																																																															2,912	0
Issuance of stock and warrants for cash, net of offering costs																																																																																																																															$ 0	$ 0	14,460,155	0	0	14,460,155
Beneficial conversion feature of preferred stock																															$ 0	$ 0	$ 8,155,212	$ 0	$ 0	$ 8,155,212																																																																																				$ 0	$ 0	$ 1,838,422	$ 0	$ 0	$ 1,838,422
Deemed dividend on preferred stock																																																																																																$ 0	$ 0	$ (8,155,212)	$ 0	$ 0	$ (8,155,212)	$ 0	$ 0	$ (1,129,742)	$ 0	$ 0	$ (1,129,742)																									(8,155,212)
Issuance of stock upon conversion of securities (in shares)																																																			(34)	34,127					0	621												0	10,594
Issuance of stock upon conversion of securities																																																			$ 0	$ 3	$ (3)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 4,786	$ 0	$ 0	$ 4,786								$ 0	$ 1	$ 131,136	$ 0	$ 0	$ 131,137
Warrants issued											$ 0	$ 0	$ 5,952,516	$ 0	$ 0	$ 5,952,516	$ 986,526	$ 986,526	$ 0	$ 0		$ 0	$ 0		$ 0	$ 0	$ 1,252,558	$ 0	$ 0	$ 1,252,558
Deemed dividend on preferred stock exchanges																																																																																																																																				0
Dividends on preferred stock																																																																																																																															$ 0	$ 0	(412,829)	0	0	(412,829)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																																																																																																																															0	149,520
Issuance of common stock at-the-market for cash, net of offering costs																																																																																																																															$ 0	$ 15	988,333	0	0	988,348
Common stock and warrants issued to consultants (in shares)																																																																																																																															0	13,284
Common stock and warrants issued to consultants																																																																																																																															$ 0	$ 1	109,604	0	0	109,605
Settlement with former placement agent																																																																																																																															0	0	85,770	0		85,770
Stock-based compensation																																																																																																																															0	0	396,809	0	0	396,809
Foreign currency translation adjustment																																																																																																																															0	0	0	0	55,007	55,007
Net loss																																																																																																																															$ 0	$ 0	0	(15,271,074)	0	(15,271,074)
Balance (in shares) at Sep. 30, 2020																																																																																																																															2,878	2,888,198
Balance at Sep. 30, 2020																																																																																																																															$ 0	$ 288	93,242,304	(77,965,806)	(1,211,548)	14,065,238
Balance (in shares) at Jun. 30, 2020																																																																																																																															0	2,850,285
Balance at Jun. 30, 2020																																																																																																																															$ 0	$ 285	73,126,945	(72,651,900)	(1,272,780)	(797,450)
Issuance of stock and warrants for cash, net of offering costs (in shares)																																																																																																																															2,912	0
Issuance of stock and warrants for cash, net of offering costs																																																																																																																															$ 0	$ 0	14,460,155	0	0	14,460,155
Beneficial conversion feature of preferred stock																																																																																																																															0	0	8,155,212	0	0	8,155,212
Deemed dividend on preferred stock																																																																																																												$ 0	$ 0	$ (8,155,212)	$ 0	$ 0	$ (8,155,212)	$ 0	$ 0	$ (1,129,742)	$ 0	$ 0	$ (1,129,742)													(8,155,212)
Issuance of stock upon conversion of securities (in shares)																																																																												(34)	34,127					0	621
Issuance of stock upon conversion of securities																																																																												$ 0	$ 3	$ (3)	$ 0		$ 0	$ 0	$ 0	$ 4,786	$ 0	$ 0	$ 4,786
Warrants issued											0	0	5,952,516	0	0	5,952,516			$ 0	$ 0	$ 986,526	$ 0	$ 0	$ 986,526
Deemed dividend on preferred stock exchanges																																																																																																																																				0
Dividends on preferred stock																																																																																																																															$ 0	$ 0	(412,829)	0	0	(412,829)
Common stock and warrants issued to consultants (in shares)																																																																																																																															0	3,165
Common stock and warrants issued to consultants																																																																																																																															$ 0	$ 0	22,500	0	0	22,500
Settlement with former placement agent																																																																																																																															0	0	85,770	0		85,770
Stock-based compensation																																																																																																																															0	0	145,680	0	0	145,680
Foreign currency translation adjustment																																																																																																																															0	0	0	0	61,232	61,232
Net loss																																																																																																																															$ 0	$ 0	0	(5,313,906)	0	(5,313,906)
Balance (in shares) at Sep. 30, 2020																																																																																																																															2,878	2,888,198
Balance at Sep. 30, 2020																																																																																																																															$ 0	$ 288	93,242,304	(77,965,806)	(1,211,548)	14,065,238
Balance (in shares) at Dec. 31, 2020																																																																																																																														0	2,774	3,115,031
Balance at Dec. 31, 2020																																																																																																																														$ 0	$ 0	$ 312	93,837,739	(95,366,198)	(1,112,546)	(2,640,693)
Issuance of stock and warrants for cash, net of offering costs (in shares)	10,667						1,625,454
Issuance of stock and warrants for cash, net of offering costs	$ 1	$ 7,105,167	$ 7,105,168				$ 163	$ 14,155,887	$ 14,156,050
Issuance of preferred stock for license acquired (in shares)																																																																																																																														3,290	0	0
Issuance of preferred stock for license acquired																																																																																																																														$ 1	$ 0	$ 0	2,467,648	0	0	2,467,649
Beneficial conversion feature of preferred stock																																																																																																																														0	0	0	4,507,125	0	0	4,507,125
Deemed dividend on preferred stock																																																																																								$ 0	$ 0	$ 0	$ (4,507,125)	$ 0	$ 0	$ (4,507,125)																																						(4,507,125)
Issuance of stock upon conversion of securities (in shares)																																					19,140	(1,839)	0					0	(259)	258,278																	(33,097)	0	3,125,460
Issuance of stock upon conversion of securities																																					$ 1	$ 0	$ 0	$ (1,431)	$ 0	$ 0	$ (1,430)	$ 0	$ 0	$ 26	$ (26)	$ 0	$ 0	$ 0													$ (3)	$ 0	$ 312	$ (309)	$ 0	$ 0	$ 0
Warrants issued										$ 0	$ 0	$ 0	$ 21,009,683	$ 0	$ 0	$ 21,009,683
Deemed dividend on preferred stock exchanges																																																																					$ (21,000,000)																										$ 0	$ 0	$ 0	$ (21,008,253)	$ 0	$ 0	$ (21,008,253)																															(21,008,253)
Dividends on preferred stock																																																																																																																														$ 0	$ 0	$ 0	(349,132)	0	0	(349,132)
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares)																																																																																																																														0	0	(1,706)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																																																																																																																														0	0	1,651,225
Issuance of common stock at-the-market for cash, net of offering costs																																																																																																																														$ 0	$ 0	$ 165	8,325,030	0	0	8,325,195
Common stock issued for intellectual property acquired, net (in shares)																																																																																																																														0	0	624,025
Common stock issued for intellectual property acquired, net																																																																																																																														$ 0	$ 0	$ 62	3,999,938	0	0	4,000,000
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares)																																																																																																																														0	0	(332,913)
Common stock cancelled in connection with acquisition of First Wave Bio, Inc.																																																																																																																														$ 0	$ 0	$ (33)	33	0	0	0
Common stock issued upon exercise of warrants (in shares)																																																																																																																														0	0	945,644
Common stock issued upon exercise of warrants																																																																																																																														$ 0	$ 0	$ 94	4,906,536	0	0	4,906,630
Common stock and warrants issued to consultants (in shares)																																																																																																																														0	0	97,230
Common stock and warrants issued to consultants																																																																																																																														$ 0	$ 0	$ 10	1,215,849	0	0	$ 1,215,859
Settlement with former placement agent (in shares)																																																																																																																														0	0	7,500				7,500
Settlement with former placement agent																																																																																																																														$ 0	$ 0	$ 1	94,498	0	0	$ 94,499
Stock-based compensation																																																																																																																														0	0	0	1,268,710	0	0	1,268,710
Foreign currency translation adjustment																																																																																																																														0	0	0	0	0	(154,561)	(154,561)
Net loss																																																																																																																														$ 0	$ 0	$ 0	0	(47,365,362)	0	(47,365,362)
Balance (in shares) at Sep. 30, 2021																																																																																																																														0	676	11,115,228
Balance at Sep. 30, 2021																																																																																																																														$ 0	$ 0	$ 1,112	137,027,567	(142,731,560)	(1,267,107)	(6,969,988)
Balance (in shares) at Jun. 30, 2021																																																																																																																														0	676	8,258,507
Balance at Jun. 30, 2021																																																																																																																														$ 0	$ 0	$ 826	120,592,372	(112,330,770)	(1,225,503)	7,036,924
Issuance of stock and warrants for cash, net of offering costs (in shares)				1,045,454
Issuance of stock and warrants for cash, net of offering costs				$ 105	$ 5,096,655	$ 5,096,760
Deemed dividend on preferred stock																																																																																																																																				0
Deemed dividend on preferred stock exchanges																																																																																																																																				0
Dividends on preferred stock																																																																																																																														$ 0	$ 0	$ 0	(118,089)	0	0	(118,089)
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares)																																																																																																																														0	0	(1,706)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																																																																																																																														0	0	1,501,661
Issuance of common stock at-the-market for cash, net of offering costs																																																																																																																														$ 0	$ 0	$ 150	7,150,697	0	0	7,150,847
Common stock issued for intellectual property acquired, net (in shares)																																																																																																																														0	0	624,025
Common stock issued for intellectual property acquired, net																																																																																																																														$ 0	$ 0	$ 62	3,999,938	0	0	4,000,000
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares)																																																																																																																														0	0	(332,913)
Common stock cancelled in connection with acquisition of First Wave Bio, Inc.																																																																																																																														$ 0	$ 0	$ (33)	33	0	0	0
Common stock and warrants issued to consultants (in shares)																																																																																																																														0	0	20,200
Common stock and warrants issued to consultants																																																																																																																														$ 0	$ 0	$ 2	123,547	0	0	123,549
Stock-based compensation																																																																																																																														0	0	0	182,414	0	0	182,414
Foreign currency translation adjustment																																																																																																																														0	0	0	0	0	(41,604)	(41,604)
Net loss																																																																																																																														$ 0	$ 0	$ 0	0	(30,400,788)	0	(30,400,788)
Balance (in shares) at Sep. 30, 2021																																																																																																																														0	676	11,115,228
Balance at Sep. 30, 2021																																																																																																																														$ 0	$ 0	$ 1,112	$ 137,027,567	$ (142,731,560)	$ (1,267,107)	$ (6,969,988)

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)	Sep. 13, 2021	Sep. 30, 2021	Sep. 30, 2021
Reverse Stock Split [Member]
Stock split, conversion ratio	10		10
Stock split, conversion ratio		10

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (47,365,362)	$ (15,271,074)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	9,390	26,556
Amortization	395,661	395,661
Non-cash lease expense	(4,855)	(4,855)
Common stock issued to settle accounts payable	0	131,137
Change in fair value of liability	(532,353)	0
Stock-based compensation	1,268,710	369,517
Restricted stock granted to employees/directors	0	27,292
Common stock granted to consultants	1,310,358	109,605
Accreted interest on convertible debt	0	234,334
Accretion of debt discount	0	4,580,167
Loss on debt extinguishment	0	609,998
Gain on settlement	0	(211,430)
Beneficial conversion feature related to promissory note exchange	0	798,413
Changes in assets and liabilities:
Accounts receivables	0	(220,094)
Other receivables	551,489	2,121,336
Prepaid expenses	964,310	446,766
Right of use assets	(289,409)	0
Deposits	(16,114)	(4,180)
Accounts payable and accrued expenses	16,897,303	90,147
Accrued dividends payable	0	408,043
Other liabilities	385,440	31,104
Net cash used in operating activities	(26,425,432)	(5,331,557)
Cash flows from investing activities:
Purchase of property and equipment	(71,448)	(2,808)
Payment made related to license agreement	(10,250,000)	0
Net cash used in investing activities	(10,321,448)	(2,808)
Cash flows from financing activities:
Proceeds from issuance of notes payable, net	0	179,408
Proceeds from issuance of preferred stock, net	7,105,168	13,197,740
Proceeds from issuance of common stock, net	18,156,050	988,348
Proceeds from exercise of warrants	4,906,630	0
Proceeds from issuance of convertible debt, net	0	3,227,002
Issuance of common stock at-the-market for cash, net of offering costs	8,325,195	0
Repayments of convertible debt	0	(475,000)
Repayments of note payable	(552,405)	(623,772)
Net cash provided by financing activities	37,940,638	16,493,726
Increase in cash	1,193,758	11,159,361
Effect of exchange rate changes on cash	(45,254)	33,523
Cash, beginning balance	6,062,141	175,796
Cash, ending balance	7,210,645	11,368,680
Supplemental disclosures of cash flow information:
Cash paid for interest	0	105,460
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Deemed dividend on preferred stock issuances	(4,507,125)	(8,155,212)
Deemed dividend on preferred stock exchanges	(21,008,253)	0
Accrued dividends on preferred stock	(349,132)	(408,043)
Issuance of preferred stock to settle liability related to license agreement	2,467,649	0
Exchange of promissory notes into preferred stock and warrants	$ 0	$ (609,998)

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 The Company AzurRx BioPharma, Inc. (“ AzurRx First Wave Parent September 21, 2021, FWB Company 33749P101 September 22, 2021. On September 13, 2021, Also, on September 13, 2021, ten one 1 1 The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (“ GI The Company is currently focused on developing its pipeline of gut-restricted GI clinical drug candidates, including niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase (formerly MS1819 The Company’s niclosamide programs leverage proprietary oral and topical formulations to address multiple GI conditions, including inflammatory bowel diseases (“IBD”) indications and viral diseases. The Company is currently advancing two 2 2 19” April 2021, 2 19 September 2021, 2 October 2021 first Additionally, the Company plans to clinically advance FW-ICI-AC for Immune Checkpoint Inhibitor-associated colitis (“ ICI-AC 2022, IND September 2021. two UC CD The Company’s adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (“ EPI CF CP March 2021, 2b 2 2021, 2 The Company is developing its drug candidates for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. The Company’s mission is to help protect the health and restore quality of life for the millions of people afflicted by these GI diseases. Since its inception, the Company has devoted substantially all its efforts to research and development, business development, and raising capital, and has primarily financed its operations through issuance of common stock, convertible preferred stock, convertible debt, and other debt/equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID- 19 19 In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the biotechnology and pharmaceutical industries with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its drug candidates; delays or problems in the manufacture and supply of its drug candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or drug candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID- 19 may The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2020, not may not 10 December 31, 2020, March 31, 2021. Going Concern Uncertainty The accompanying unaudited interim consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. On September 30, 2021, November 15, 2021, January 2022 August 2022 September 2022 July 2023 19 Without adequate working capital, the Company may not not

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2 Use of Estimates The accompanying unaudited consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets, and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three September 30, 2021, December 31, 2020, Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may September 30, 2021, December 31, 2020, one not The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. Debt Instruments Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved. Debt Issuance Costs Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method. Equity-Based Payments to Non-Employees Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018 07, Fair Value Measurements The Company follows Accounting Standards Codification ( ASC 820 10, ( ASC 820 As a basis for considering such assumptions, a three Level 1: Level 2: Level 3: no In certain cases, the inputs used to measure fair value may The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may not September 30, 2021. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, ( ASC 360 may not not September 30, 2021. Income Taxes Income taxes are recorded in accordance with ASC 740, ( ASC 740 not not The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. not not September 30, 2021 December 31, 2020, not three Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ ROU not may 15 License Agreements As more fully discussed in Note 14, FWB License Agreement 19 19 no no September 13, 2021, Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third third CMC MS1819 Research and Development Intellectual Property Acquired The Company concluded that its acquisition of FWB completed on September 13, 2021 805, not The former FWB stockholders are also entitled to (i) up to $207.0 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals for the use of the acquired assets, and (ii) certain revenue-sharing. The potential milestone payments and revenue share are not September 30, 2021. may Stock-Based Compensation The Company’s board of directors (the “ Board 2014 2014 May 12, 2014, 2020 September 11, 2020 ( 2020 2020 no 2014 718, ASC 718 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Recent Accounting Pronouncements In August 2020, 2020 06 SEC December 15, 2023.

Note 3 - Fair Value Disclosures

Note 3 - Fair Value Disclosures	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3 Fair Value Disclosures Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value September 30, 2021: Cash and cash equivalents $ 7,210,645 $ 6,709,028 $ 501,617 $ - $ 7,210,645 December 31, 2020: Cash and cash equivalents $ 6,062,141 $ 3,000,184 $ 3,061,957 $ - $ 6,062,141 Other receivables $ 551,489 $ - $ - $ 551,489 $ 551,489 Note payable $ 552,405 $ - $ - $ 552,405 $ 552,405 On September 30, 2021, December 31, 2020, 1 The fair value of other receivables approximates carrying value as these consist primarily of French research and development tax credits that are normally received the following year. The fair value of the note payable in connection with the financing of directors and officer’s liability insurance approximates carrying value due to the terms of such instruments and applicable interest rates.

Note 4 - Asset Acquisition

Note 4 - Asset Acquisition	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Asset Acquisition [Text Block]	Note 4 Asset Acquisition The Asset Acquisition On September 13, 2021, September 13, 2021 ( FWB Merger Agreement Merger Sub September 13, 2021, FWB Merger At the effective time of the FWB Merger, the former FWB stockholders received an applicable pro rata share of (i) $3.0 million in cash and (ii) 624,025 shares of the Common Stock. The remaining non-contingent purchase price is payable to the former FWB stockholders on a pro rata basis upon the Company’s payment of (i) $8.0 million in cash, payable within 45 March 31, 2022. November 15, 2021, $500,000 January 2022 August 2022 $1.0 September 2022 July 2023 19 no The former FWB stockholders are also entitled to up to $207 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals relating to the use of the acquired assets. All milestone payments will be payable in cash, provided that 25% of the milestone payments attributable to a certain IBD indications may third Accounting Treatment The Company concluded that the FWB Merger should be accounted for as an asset acquisition under ASC 805 not not The potential milestone payments and revenue share are not September 30, 2021. may

Note 5 - Property, Equipment an

Note 5 - Property, Equipment and Leasehold Improvements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 5 Property, equipment, and leasehold improvements consisted of the following: September 30, December 31, 2021 2020 Laboratory equipment $ - $ 2,410 Computer equipment and software 11,540 19,676 Office equipment 48,277 5,483 Leasehold improvements 28,000 29,163 Total property, plant, and equipment 87,817 56,732 Less accumulated depreciation (7,430 ) (38,403 ) Property, plant and equipment, net $ 80,387 $ 18,329 Depreciation expense for the three September 30, 2021 2020 nine September 30, 2021 2020 $9,000 $27,000, During the nine September 30, 2021,

Note 6 - Intangible Assets and

Note 6 - Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 6 Patents Pursuant to the Mayoly asset purchase agreement entered in March 2019 ( 14 MS1819 Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 449,280 Due to Mayoly at December 31, 2020 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745 Patents are as follows: September 30, December 31, 2021 2020 Patents $ 3,802,745 $ 3,802,745 Less accumulated amortization (1,318,870 ) (923,209 ) Patents, net $ 2,483,875 $ 2,879,536 Amortization expense was approximately $132,000 and $132,000 for the three September 30, 2021, 2020, Amortization expense was approximately $396,000 and $396,000 for the nine September 30, 2021, 2020, As of September 30, 2021, five 2021 2026 2021 (balance of year) $ 131,887 2022 527,548 2023 527,548 2024 527,548 2025 527,548 2026 241,796 Total $ 2,483,875 Goodwill is as follows: Goodwill Balance on January 1, 2020 $ 1,886,686 Foreign currency translation 167,362 Balance on December 31, 2020 2,054,048 Foreign currency translation (109,306 ) Balance on September 30, 2021 $ 1,944,742

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 Accounts payable and accrued expenses consisted of the following: September 30, December 31, 2021 2020 Trade payables $ 18,447,834 $ 1,558,591 Accrued expenses 135,072 127,012 Total accounts payable and accrued expenses $ 18,582,906 $ 1,685,603 The increase in trade payables as of September 30, 2021 December 31, 2020

Note 8 - Note Payable

Note 8 - Note Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 8 Directors and Officer s Liability Insurance On November 30, 2020, September 30, 2021 December 31, 2020,

Note 9 - Convertible Debt

Note 9 - Convertible Debt	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Convertible Debt Disclosure [Text Block]	Note 9 The ADEC Note Offering On February 14, 2019, ADEC two ADEC Note, ADEC Notes ADEC Note Offering In December 2019, January 2020, ADEC Notes Senior Convertible Promissory Note Offering On December 20, 2019, Promissory Note Promissory Notes Note Investors Note Warrants Promissory Promissory Note Offering The Promissory Notes were scheduled to mature on September 20, 2020, Promissory Note Conversion Shares Conversion Option Prepayment Option On January 2, 2020, January 3, 2020, January 9, 2020, As additional consideration for the execution of the Promissory NPA, each Note Investor also received Note Warrants to purchase that number of shares of Common Stock equal to one Note Warrant Shares five July 2020, 11, September 2020. In connection with the three January 2020 Placement Agent Warrants five The Company determined the Prepayment Option feature represents a contingent call option. The Company evaluated the Prepayment Option in accordance with ASC 815 15 25. not 815 15 25. 815 not The Company evaluated the Promissory Notes for a beneficial conversion feature in accordance with ASC 470 20. Pursuant to the January 2020 first On June 1, 2020, December 20, 2019, Note Amendment 470 50 not no During the three September 30, 2020, During the nine September 30, 2020,

Note 10 - Other Liabilities

Note 10 - Other Liabilities	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	Note 10 Other liabilities consisted of the following: September 30, December 31, 2021 2020 Current Lease liabilities $ 94,794 $ 57,417 Other liabilities 71,497 - $ 166,291 $ 57,417 Long-term Lease liabilities $ 295,689 $ 19,123 $ 295,689 $ 19,123

Note 11 - Equity

Note 11 - Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 11 Equity The Company’s certificate of incorporation, as amended and restated (the “ Charter On February 24, 2021 2021 one 1:5 one 1:10 one 2021 Reverse Split September 13, 2021, ten one 1 Common Stock The Company had 11,115,228 and 3,115,031 shares of its Common Stock issued and outstanding on September 30, 2021 December 31, 2020, Each holder of Common Stock is entitled to one Bylaws not In addition, the holders of Common Stock will be entitled to receive ratably such dividends, if any, as may Holders of Common Stock have no no may may Preferred Stock The Company has 10,000,000 shares of preferred stock, par value $0.0001 per share, authorized and available for issuance in one may no may On July 16, 2020, may not may September 30, 2021, On January 5, 2021, not September 30, 2021, On September 30, 2021, Series B Convertible Preferred Stock Pursuant to the Certificate of Designation of Rights and Preferences of the Series B Preferred Stock (the “ Series B Certificate of Designation Ranking The Series B Preferred Stock will rank senior to the Common Stock with respect to distributions of assets upon the liquidation, dissolution or winding up of the Company. Stated Value Each share of Series B Preferred Stock has a stated value of $7,700, subject to adjustment for stock splits, combinations, and similar events (the “ Series B Stated Value Dividends Each holder of shares of Series B Preferred Stock, in preference and priority to the holders of all other classes or series of stock of the Company, is entitled to receive dividends, commencing from the date of issuance. Such dividends may June December December 31, 2020, not not may September 30, 2021, Liquidation Preference; Liquidation Rights Under the Certificate of Designations, each share of Series B Preferred Stock carries a liquidation preference equal to the Series B Stated Value (as adjusted thereunder) plus accrued and unpaid dividends thereon (the “ Liquidation Preference If the Company voluntarily or involuntarily liquidates, dissolves or winds up its affairs, each holder of the Series B Preferred Stock will be entitled to receive out of the Company’s assets available for distribution to stockholders, after satisfaction of liabilities to creditors, if any, but before any distribution of assets is made on the Common Stock or any of the Company’s shares of stock ranking junior as to such a distribution to the Series B Preferred Stock, a liquidating distribution in the amount of the Stated Value of all such holder’s Series B Preferred Stock plus all accrued and unpaid dividends thereon. On September 30, 2021, Conversion Each share of Series B Preferred Stock will be convertible at the holder’s option at any time, into Common Stock at a conversion rate equal to the quotient of (i) the Series B Stated Value divided by (ii) the initial conversion price of $7.70, subject to specified adjustments for stock splits, cash or stock dividends, reorganizations, reclassifications other similar events as set forth in the Series B Certificate of Designations. In addition, at any time after the six Automatic Conversion may not Most Favored Nations (MFN) Exchange Right In the event the Company effects any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, or a combination of units thereof (a “ Subsequent Financing Series B Exchange Amount Series B Exchange Right Voting The holders of the Series B Preferred Stock, voting as a separate class, have customary consent rights with respect to certain corporate actions of the Company. The Company may not first 2014 The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 2014 May 12, 2014. 2020 September 11, 2020, 2014 The Company issued an aggregate of 79,500 stock options, during the nine September 30, 2020, 2014 13 As of September 30, 2021, 2014 RSUs 2020 The Company’s Board and stockholders adopted and approved the 2020 2020 September 11, 2020. 2020 January 1 ten December 31 not 2014 2020 ISOs 2020 The Company issued an aggregate of 175,246 stock options during the nine September 30, 2021, 2020 13 As of September 30, 2021, 2020 Equity Line with Lincoln Park In November 2019, Equity Line Agreement Lincoln Park Registration Rights Agreement Equity Line Commitment Shares no The remaining shares of Common Stock that may may 30 December 31, 2019 January 14, 2020. There is approximately $14.0 million of availability left for issuance pursuant to the Equity Line Agreement. The Company issued an aggregate of 0, and 149,519 shares of Common Stock, during the nine September 30, 2021 2020, At The Market Agreement with H.C. Wainwright On May 26, 2021, Wainwright may may 415 4 1933, May 26, 2021, three September 30, 2021, nine September 30, 2021, Common Stock Issuances 2021 During the three September 30, 2021, During the three September 30, 2021, July 2021 During the three September 30, 2021, 4 During the three September 30, 2021, 1 September 13, 2021. During the nine September 30, 2021, During the nine September 30, 2021, $94,000 During the nine September 30, 2021, During the nine September 30, 2021, 12 During the nine September 30, 2021, During the nine September 30, 2021, March 2021 July 2021 2020 During the three September 30, 2020, not During the three September 30, 2020, 34.127448 During the three September 30, 2020, During the nine September 30, 2020, $112,000 During the nine September 30, 2020, Restricted Stock and Restricted Stock Units Restricted stock refers to shares of Common Stock subject to vesting based on certain service, performance, and market conditions. Restricted stock unit awards refer to an award under the 2014 2020 During the three nine September 30, 2021, During the three September 30, 2020, During the nine September 30, 2020, During the three nine September 30, 2020, As of September 30, 2021, first MS1819 20 not September 30, 2021. As of September 30, 2020, first MS1819 20 not September 30, 2020. The Series B Private Placement and the Exchange On July 16, 2020 ( Series B Closing Date Series B Private Placement Series B Purchase Agreement Series B Investors Series B Preferred Stock Series B Warrants In connection with the Series B Private Placement, an aggregate of approximately 1,975.58 shares of Series B Preferred Stock initially convertible into 1,975,574 shares of Common Stock and related 987,783 Series B Warrants were issued for cash consideration, resulting in aggregate gross proceeds of approximately $15.2 million and aggregate net proceeds to the Company of approximately $13.2 million after deducting placement agent compensation and offering expenses. An aggregate of approximately 937.00 shares of Series B Preferred Stock initially convertible into 937,000 shares of Common Stock and related Series B Warrants to purchase 468,499 shares of Common Stock were issued to certain Series B Investors (the “ Exchange Investors Promissory Notes December 20, 2019 January 9, 2020 ( Exchange Exchange Addendum Exchange Warrants Pursuant to the Series B Private Placement and the Series B Purchase Agreement, for purposes of complying with Nasdaq Listing Rule 5635 5635 not 60 2020 2020 not 9 0th September 11, 2020, 2020 The Company prepaid the remaining outstanding balance of $25,000 aggregate principal amount of Promissory Notes, together with accrued and unpaid interest thereon through the prepayment date of approximately $1,000, held by those holders who did not January 2021 On December 31, 2020, Series C Purchase Agreement January 2021 Registered Direct Offering Concurrently with the Registered Direct Offering, in a private placement offering pursuant to the Series C Purchase Agreement (the “ January 2021 Private Placement, January 2021 January 2021 January 2021 January 2021 July 6, 2026. In connection with the January 2021 December 31, 2020, 1 No. 333 252087 January 2021 January 2021 January 21, 2021. On January 6, 2021, January 2021 January 2021 The Company paid the placement agent a cash fee equal to 8.0% and a management fee equal to 1.0% of the aggregate gross proceeds received by the Company in the January 2021 January 2021 January 2021 January 2021 January 2021 Pursuant to the January 2021 not March 31, 2021 2021 January 2021 January 2021 On February 24, 2021, 2021 Accounting for the January 2021 Upon receiving the 2021 February 24, 2021, no not no 1 may 2 Because the Series C Preferred Stock contains certain embedded features that could affect the ultimate settlement of the Series C Preferred Stock, the Company analyzed the instrument for embedded derivatives that require bifurcation. The Company’s analysis began with determining whether the Series C Preferred Stock is more akin to equity or debt. The Company evaluated the following criteria/features in this determination: redemption, voting rights, collateral requirements, covenant provisions, creditor and liquidation rights, dividends, and conversion rights. The Company determined that the Series C Preferred Stock was more akin to equity than to debt when evaluating the economic characteristics and risks of the entire Series C Preferred Stock, including the embedded features. The Company then evaluated the embedded features to determine whether their economic characteristics and risks were clearly and closely related to the economic characteristics and risks of the Series C Preferred Stock. Since the Series C Preferred Stock was determined to be more akin to equity than debt, and the underlying that causes the value of the embedded features to fluctuate would be the value of the Company’s common stock, the embedded features were considered clearly and closely related to the Series C Preferred Stock. As a result, the embedded features would not The Company concluded the freestanding January 2021 not The proceeds from the January 2021 January 2021 January 2021 Series B Most Favored Nations (MFN) Exchanges into the January 2021 Subject to the consummating the January 2021 January 2021 During the nine September 30, 2021, January 2021 February 24, 2021, 2021 February 24, 2021, As a result, as of September 30, 2021, may January 2021 January 2021 no January 2021 Accounting for the Series B Exchanges into the January 2021 During the nine September 30, 2021, February 24, 2021. nine September 30, 2021, January 2021 March 2021 On March 7, 2021, March 2021 March 2021 March 2021 Pre-Funded Warrants no March 2021 Warrants five March 2021 On March 10, 2021, March 2021 March 2021 March 2021 The Company paid the placement agent a cash fee equal to 8.0% of the aggregate gross proceeds received by the Company, or approximately $800,000. The Company also agreed to issue the placement agent or its designees warrants (the “ March 2021 March 2021 March 2021 March 2021 The March 2021 3 No. 333 231954 June 21, 2019, June 25, 2019. March 2021 The Company concluded the freestanding March 2021 March 2021 not July 2021 On July 22, 2021, July 27, 2021, 30 July 27, 2021. The Company received net proceeds from the offering of approximately $5.1 million. The Company intends to use the net proceeds from the offering for milestone payments due under the Company’s license agreements and for other general corporate purposes. The Company paid Wainwright an underwriting discount equal to 8.0% of the gross proceeds of the offering, and reimbursed Wainwright for a non-accountable expense allowance of $35,000, $125,000 in legal fees and $15,950 for clearing expenses. Additionally, as partial compensation for Wainwright’s services as underwriter in the offering, the Company issued to Wainwright (or its designees) warrants to purchase 73,181 shares of Common Stock equal to 7.0% of the aggregate number of shares of Common Stock sold in the offering (the “ Wainwright Warrants five 5 not The Company concluded the freestanding Wainwright Warrants did not Most Favored Nations (MFN) Exchange Right Under the Series B Certificate of Designations, each holder of the Series B Preferred Stock may 3 9 144 As of September 30, 2021, 1,839.76 $14.4 1,914,024 January 2021 1,914,014 As a result, as of September 30, 2021, 676.05 $349,000 may 7,406 740,612 January 2021 740,612 January 2021 1,633,720 May 26, 2021 ( ATM Agreement no

Note 12 - Warrants

Note 12 - Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Warrants Disclosure [Text Block]	Note 12 Warrants During the three September 30, 2021, July 2021 July 2021 11. July 2021 July 22, 2021, five no 11 During the nine September 30, 2021, January 2021 11. January 2021 April 1, 2021 June 9, 2021, July 6, 2026. During the nine September 30, 2021, January 2021 January 2021 11. January 2021 January 6, 2021, July 6, 2026. January 2021 February 24, 2021. 11 During the nine September 30, 2021, January 2021 11. January 6, 2021, not 11 During the nine September 30, 2021, January 2021 January 2021 11. January 2021 January 6, 2021, July 6, 2026. no 11 During the nine September 30, 2021, January 2021 11. January 2021 January 13, 2021 June 9, 2021, July 6, 2026. February 24, 2021. During the nine September 30, 2021, March 2021 March 2021 11. March 2021 March 10, 2021, five 11 During the nine September 30, 2021, March 2021 11. March 10, 2021, not 11 During the nine September 30, 2021, March 2021 March 2021 11. March 2021 March 10, 2021, five no 11 During the nine September 30, 2021, February 8, 2021, four During the three September 30, 2021, During the nine September 30, 2021, During the nine September 30, 2021, January 2021 March 2021, During the nine September 30, 2020, January 2020 9. January 2, 2020 January 9, 2020, six 6 five During the nine September 30, 2020, January 2020 January 2, 2020 January 9, 2020, five For the three nine September 30, 2020, 11. July 16, 2020, six 6 five 11 For the three nine September 30, 2020, 11 11. July 16, 2020, six 6 five 9 For the three nine September 30, 2020, July 11. July July 16, 2020, six 6 five July 11 For the three nine September 30, 2020, July 14, 2020 five may six During the nine September 30, 2020, Warrant transactions for the nine September 30, 2021 2020 Exercise Weighted Price Per Average Warrants Share Price Warrants outstanding and exercisable on January 1, 2020 537,828 $10.70 - 73.70 $ 25.30 Granted during the period 1,988,165 $8.50 - 14.20 $ 8.80 Expired during the period (5,977 ) $32.50 - 73.70 $ 51.50 Exercised during the period - - - Warrants outstanding and exercisable on September 30, 2020 2,520,016 $8.50 - 73.70 $ 12.20 Warrants outstanding and exercisable on January 1, 2021 2,517,722 $8.50 - 73.70 $ 12.20 Granted during the period 3,995,602 $0.01 - 16.90 $ 7.77 Expired during the period (51,061 ) - - Exercised during the period (952,588 ) - - Warrants outstanding and exercisable on September 30, 2021 5,509,675 $6.87 - 66.00 $ 9.96 Warrants exercisable on September 30, 2021, Exercise Price Number of Shares Under Warrants Weighted Average Remaining Contract Life in Years Weighted Average Exercise Price $ 0.00 - 9.99 4,482,860 4.40 $ 10.00 - 19.99 840,745 3.62 $ 20.00 - 29.99 32,003 1.82 $ 30.00 - 39.99 61,155 0.61 $ 40.00 - 49.99 16,425 0.53 $ 50.00 - 59.99 72,714 0.47 $ 60.00 - 69.99 3,773 0.17 Totals 5,509,675 4.16 $ 9.96 The weighted average fair value of warrants granted during the nine September 30, 2021, 2020, September 30, 2021 Expected life (in years) 5.19 Volatility 83.8 - 90.8 % Risk-free interest rate 0.28 - 1.67 Dividend yield -%

Note 13 - Stock Options

Note 13 - Stock Options	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Shareholders' Equity and Share-based Payments [Text Block]	Note 13 Under the 2014 2020 No not not, not On June 30, 2021, 2014 Prior Awards New Awards 2020 July 27, 2020, August 11, 2020, 2020 The terms of the New Awards to Mr. Sapirstein (the “ New Sapirstein Awards 18 first February 16, 2022, ( not 718 no no The terms of the New Awards to Mr. Schneiderman (the “ New Schneiderman Awards 2 1 19 not 718 no no During the three September 30, 2021, 2020 ten three During the three September 30, 2021, 2014 During the nine September 30, 2021, 2020 ten three During the nine September 30, 2021, 2014 During the nine September 30, 2021, During the nine September 30, 2021, 2 2 2 2 2 1 MS1819 19 During the three September 30, 2020, ten During the three September 30, 2020, January 2, 2020, 2014 2014 162 January 2, 2020, three 36 January 2, 2020. 718. January 1, 2023. During the nine September 30, 2020, ten three During the nine September 30, 2020, ten During the nine September 30, 2020, During the three September 30, 2020, During the nine September 30, 2020, During the nine September 30, 2020, 2 The fair values were estimated on the grant dates using the Black-Scholes option-pricing model with the following weighted-average assumptions: September 30, 2021 Contractual term (in years) 10 Volatility 83.8 - 90.6 % Risk-free interest rate 83.9 - 1.69 Dividend yield - % The expected term of the options is based on expected future employee exercise behavior. Volatility is based on the historical volatility of the Company’s Common Stock if available or of several public entities that are similar to the Company. The Company bases volatility this way because it may not not not During the nine September 30, 2021 2020, 2014 2020 Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2020 167,750 $ 21.70 5.37 $ - Granted during the period 287,001 $ 8.90 9.79 - Canceled during the period (23,500 ) $ 19.40 3.28 - Stock options outstanding on September 30, 2020 431,251 $ 13.80 6.52 $ - Exercisable on September 30, 2020 131,275 $ 22.20 6.09 $ - Non-vested stock options outstanding on January 1, 2020 88,350 $ 13.30 6.26 $ - Granted during the period 287,001 $ 10.00 10.00 - Vested during the period (59,375 ) $ 25.90 6.88 - Canceled during the period (16,000 ) $ 13.00 7.10 - Non-vested stock options outstanding on September 30, 2020 299,976 $ 9.80 8.75 $ - Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2021 407,026 12.46 7.94 $ - Granted during the period 175,246 $ 8.61 10.00 - Canceled during the period (134,476 ) $ 10.47 2.87 - Stock options outstanding on September 30, 2021 447,796 $ 11.55 7.57 - Exercisable on September 30, 2021 280,272 $ 13.76 6.78 $ - Non-vested stock options outstanding on January 1, 2021 274,065 $ 9.90 8.42 - Granted during the period 175,246 $ 8.61 10.00 - Vested during the period (185,870 ) $ 10.38 - - Canceled during the period (95,917 ) $ - - - Non-vested stock options outstanding on September 30, 2021 167,524 $ 8.44 8.87 $ - As of September 30, 2021, 1.85 3 MS1819. MS1819 MS1819 December 31, 2021. As of September 30, 2020, of.8.75 2 2 2 December 31, 2021.

Note 14 - Agreements

Note 14 - Agreements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Agreements Disclosure [Text Block]	Note 14 Agreements License Agreement with First Wave Bio, Inc. (FWB) On December 31, 2020, Niclosamide Product 19 In consideration of the license and other rights granted by FWB, the Company agreed to pay FWB a $9.0 million upfront cash payment due within 10 January 2021 June 30, 2021, July 2021. September 30, 2021, 19 five December 31, 2020, On January 8, 2021, FWB Purchase Agreement The conversion price of the Series C Preferred Stock was determined to be beneficial and, as a result, the Company recorded a deemed dividend of approximately $230,000 equal to the intrinsic value of the beneficial conversion feature and recognized on the issuance date and recorded as a reduction of income available to common stockholders in computing basic and diluted loss per share. Upon the 2021 February 24, 2021, December 31, 2020 Following the 2021 Upon consummating the FWB Merger on September 13, 2021, Mayoly Agreement In March 2019, Mayoly Mayoly APA MS1819. JDLA MS1819 TransChem Sublicense In August 2017, 5’methylthioadenosine TransChem Licensed Patents TransChem Sublicense Agreement March 2020, sixty 60 September 30, 2021

Note 15 - Leases

Note 15 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 15 Leases The Company leases its offices and research facilities under operating leases which are subject to various rent provisions and escalation clauses. Effective June 1, 2021, sixty-three 777 502, 33431. The Company’s leases expire at various dates through 2026. not Lease expense amounted to approximately $79,000 and $55,000, respectively, for the three September 30, 2021, 2020. Lease expense amounted to approximately $186,000 and $129,000, respectively, for the nine September 30, 2021, 2020. The weighted-average remaining lease term and weighted-average discount rate under operating leases on September 30, 2021, September 30, 2021 Lease term and discount rate Weighted-average remaining lease term (years) 4.5 Weighted-average discount rate 6.91 % Maturities of operating lease liabilities on September 30, 2021, 2021 $ 57,019 2022 81,254 2023 83,691 2024 86,202 2025 88,788 Thereafter 60,593 Total lease payments 457,547 Less imputed interest (67,064 ) Present value of lease liabilities $ 390,483

Note 16 - Income Taxes

Note 16 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 16 The Company did not nine September 30, 2021 2020 December 31, 2021 2020, On September 30, 2021, December 31, 2020, 740, Accounting for Income Taxes

Note 17 - Net Loss Per Common S

Note 17 - Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 17 Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not On September 30, 2021, not September 30, 2021, not January 2021 At September 30, 2020, not At September 30, 2020, not

Note 18 - Employee Benefit Plan

Note 18 - Employee Benefit Plans	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 18 401 Since 2015, 401 All employees are eligible to participate in the plan. Employees may 100% first may Employer contributions under this 401 three September 30, 2021 2020, Employer contributions under this 401 nine September 30, 2021 2020,

Note 19 - Subsequent Events

Note 19 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 19 ATM Agreement Sales On October 4, 2021, first 2 Achievement of Milestone pursuant to FWB Merger Agreement On October 4, 2021, first 2 $2.0 $17.0 Most Favored Nations (MFN) Exchange Right Subsequent to September 30, 2021, FWB Payments Fortis Advisors LLC is the hired representative (in such capacity, the “ Representative October 29, 2021, October 28, 2021 November 15, 2021, January 2022 August 2022 September 2022 July 2023 8 September 13, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The accompanying unaudited consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets, and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three September 30, 2021, December 31, 2020,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may September 30, 2021, December 31, 2020, one not The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.
Debt, Policy [Policy Text Block]	Debt Instruments Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved. Debt Issuance Costs Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method.
Compensation Related Costs, Policy [Policy Text Block]	Equity-Based Payments to Non-Employees Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018 07,
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows Accounting Standards Codification ( ASC 820 10, ( ASC 820 As a basis for considering such assumptions, a three Level 1: Level 2: Level 3: no In certain cases, the inputs used to measure fair value may The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may not September 30, 2021. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, ( ASC 360 may not not September 30, 2021.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are recorded in accordance with ASC 740, ( ASC 740 not not The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. not not September 30, 2021 December 31, 2020, not three
Lessee, Leases [Policy Text Block]	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ ROU not may 15
License Agreement [Policy Text Block]	License Agreements As more fully discussed in Note 14, FWB License Agreement 19 19 no no September 13, 2021,
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third third CMC MS1819 Research and Development Intellectual Property Acquired The Company concluded that its acquisition of FWB completed on September 13, 2021 805, not The former FWB stockholders are also entitled to (i) up to $207.0 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals for the use of the acquired assets, and (ii) certain revenue-sharing. The potential milestone payments and revenue share are not September 30, 2021. may
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s board of directors (the “ Board 2014 2014 May 12, 2014, 2020 September 11, 2020 ( 2020 2020 no 2014 718, ASC 718 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2020, 2020 06 SEC December 15, 2023.

Note 3 - Fair Value Disclosur_2

Note 3 - Fair Value Disclosures (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value September 30, 2021: Cash and cash equivalents $ 7,210,645 $ 6,709,028 $ 501,617 $ - $ 7,210,645 December 31, 2020: Cash and cash equivalents $ 6,062,141 $ 3,000,184 $ 3,061,957 $ - $ 6,062,141 Other receivables $ 551,489 $ - $ - $ 551,489 $ 551,489 Note payable $ 552,405 $ - $ - $ 552,405 $ 552,405

Note 5 - Property, Equipment _2

Note 5 - Property, Equipment and Leasehold Improvements (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2021 2020 Laboratory equipment $ - $ 2,410 Computer equipment and software 11,540 19,676 Office equipment 48,277 5,483 Leasehold improvements 28,000 29,163 Total property, plant, and equipment 87,817 56,732 Less accumulated depreciation (7,430 ) (38,403 ) Property, plant and equipment, net $ 80,387 $ 18,329

Note 6 - Intangible Assets an_2

Note 6 - Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Patents [Table Text Block]	Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 449,280 Due to Mayoly at December 31, 2020 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, December 31, 2021 2020 Patents $ 3,802,745 $ 3,802,745 Less accumulated amortization (1,318,870 ) (923,209 ) Patents, net $ 2,483,875 $ 2,879,536
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2021 (balance of year) $ 131,887 2022 527,548 2023 527,548 2024 527,548 2025 527,548 2026 241,796 Total $ 2,483,875
Schedule of Goodwill [Table Text Block]	Goodwill Balance on January 1, 2020 $ 1,886,686 Foreign currency translation 167,362 Balance on December 31, 2020 2,054,048 Foreign currency translation (109,306 ) Balance on September 30, 2021 $ 1,944,742

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Other Assets and Other Liabilities [Table Text Block]	September 30, December 31, 2021 2020 Trade payables $ 18,447,834 $ 1,558,591 Accrued expenses 135,072 127,012 Total accounts payable and accrued expenses $ 18,582,906 $ 1,685,603

Note 10 - Other Liabilities (Ta

Note 10 - Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Other Liabilities [Table Text Block]	September 30, December 31, 2021 2020 Current Lease liabilities $ 94,794 $ 57,417 Other liabilities 71,497 - $ 166,291 $ 57,417 Long-term Lease liabilities $ 295,689 $ 19,123 $ 295,689 $ 19,123

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Weighted Price Per Average Warrants Share Price Warrants outstanding and exercisable on January 1, 2020 537,828 $10.70 - 73.70 $ 25.30 Granted during the period 1,988,165 $8.50 - 14.20 $ 8.80 Expired during the period (5,977 ) $32.50 - 73.70 $ 51.50 Exercised during the period - - - Warrants outstanding and exercisable on September 30, 2020 2,520,016 $8.50 - 73.70 $ 12.20 Warrants outstanding and exercisable on January 1, 2021 2,517,722 $8.50 - 73.70 $ 12.20 Granted during the period 3,995,602 $0.01 - 16.90 $ 7.77 Expired during the period (51,061 ) - - Exercised during the period (952,588 ) - - Warrants outstanding and exercisable on September 30, 2021 5,509,675 $6.87 - 66.00 $ 9.96
Schedule of Warrants by Exercise Price [Table Text Block]	Exercise Price Number of Shares Under Warrants Weighted Average Remaining Contract Life in Years Weighted Average Exercise Price $ 0.00 - 9.99 4,482,860 4.40 $ 10.00 - 19.99 840,745 3.62 $ 20.00 - 29.99 32,003 1.82 $ 30.00 - 39.99 61,155 0.61 $ 40.00 - 49.99 16,425 0.53 $ 50.00 - 59.99 72,714 0.47 $ 60.00 - 69.99 3,773 0.17 Totals 5,509,675 4.16 $ 9.96
Schedule of Warrant Assumptions [Table Text Block]	September 30, 2021 Expected life (in years) 5.19 Volatility 83.8 - 90.8 % Risk-free interest rate 0.28 - 1.67 Dividend yield -%

Note 13 - Stock Options (Tables

Note 13 - Stock Options (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	September 30, 2021 Contractual term (in years) 10 Volatility 83.8 - 90.6 % Risk-free interest rate 83.9 - 1.69 Dividend yield - %
Share-based Payment Arrangement, Activity [Table Text Block]	Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2020 167,750 $ 21.70 5.37 $ - Granted during the period 287,001 $ 8.90 9.79 - Canceled during the period (23,500 ) $ 19.40 3.28 - Stock options outstanding on September 30, 2020 431,251 $ 13.80 6.52 $ - Exercisable on September 30, 2020 131,275 $ 22.20 6.09 $ - Non-vested stock options outstanding on January 1, 2020 88,350 $ 13.30 6.26 $ - Granted during the period 287,001 $ 10.00 10.00 - Vested during the period (59,375 ) $ 25.90 6.88 - Canceled during the period (16,000 ) $ 13.00 7.10 - Non-vested stock options outstanding on September 30, 2020 299,976 $ 9.80 8.75 $ - Average Remaining Number Exercise Contract Intrinsic of Shares Price Life (Years) Value Stock options outstanding on January 1, 2021 407,026 12.46 7.94 $ - Granted during the period 175,246 $ 8.61 10.00 - Canceled during the period (134,476 ) $ 10.47 2.87 - Stock options outstanding on September 30, 2021 447,796 $ 11.55 7.57 - Exercisable on September 30, 2021 280,272 $ 13.76 6.78 $ - Non-vested stock options outstanding on January 1, 2021 274,065 $ 9.90 8.42 - Granted during the period 175,246 $ 8.61 10.00 - Vested during the period (185,870 ) $ 10.38 - - Canceled during the period (95,917 ) $ - - - Non-vested stock options outstanding on September 30, 2021 167,524 $ 8.44 8.87 $ -

Note 15 - Leases (Tables)

Note 15 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	September 30, 2021 Lease term and discount rate Weighted-average remaining lease term (years) 4.5 Weighted-average discount rate 6.91 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 $ 57,019 2022 81,254 2023 83,691 2024 86,202 2025 88,788 Thereafter 60,593 Total lease payments 457,547 Less imputed interest (67,064 ) Present value of lease liabilities $ 390,483

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual)	Nov. 15, 2021USD ($)	Sep. 13, 2021	Sep. 30, 2021USD ($)	Aug. 31, 2022USD ($)	Aug. 30, 2022USD ($)	Sep. 30, 2021USD ($)	Jul. 31, 2023USD ($)	Dec. 31, 2020USD ($)
Stockholders' Equity Note, Stock Split, Conversion Ratio			10
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 7,210,645			$ 7,210,645		$ 6,062,141
Retained Earnings (Accumulated Deficit), Ending Balance			$ (142,731,560)			$ (142,731,560)		$ (95,366,198)
Fortis Advisors Complaint [Member] | Forecast [Member]
Litigation Settlement, Amount Awarded to Other Party, Periodic Payment				$ 500,000	$ 500,000		$ 1,000,000
Fortis Advisors Complaint [Member] | Subsequent Event [Member]
Litigation Settlement, Amount Awarded to Other Party Immediately	$ 2,000,000
Litigation Settlement, Amount Awarded to Other Party	$ 17,000,000
AzurRx SAS [Member]
Noncontrolling Interest, Ownership Percentage by Parent			10.00%			10.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10				10

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements (Details Textual) - USD ($)	Sep. 30, 2021	Sep. 13, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Cash, Uninsured Amount	$ 300,000		$ 300,000		$ 2,700,000
Payments to Acquire Intangible Assets			10,250,000	$ 0
First Wave License Agreement [Member]
Asset Acquisition, Consideration Transferred, Total			13,300,000
Payments to Acquire Intangible Assets			10,300,000
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable			$ 3,000,000
FWB [Member]
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable		$ 4,000,000
FWB [Member] | Development Achievement Threshold [Member]
Asset Acquisition, Potential Milestone Payments		$ 207,000,000
Asset Acquisition, Consideration Transferred, Contingent Consideration	$ 0
Patents [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			7 years 2 months 12 days

Note 3 - Fair Value Disclosur_3

Note 3 - Fair Value Disclosures (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 7,210,645	$ 6,062,141
Money Market Funds [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 6,700,000	$ 3,000,000

Note 3 - Fair Value Disclosur_4

Note 3 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Reported Value Measurement [Member]
Cash and cash equivalents	$ 7,210,645	$ 6,062,141
Other receivables		551,489
Note payable		552,405
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents	7,210,645	6,062,141
Other receivables		551,489
Note payable		552,405
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	6,709,028	3,000,184
Other receivables		0
Note payable		0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	501,617	3,061,957
Other receivables		0
Note payable		0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	$ 0	0
Other receivables		551,489
Note payable		$ 552,405

Note 4 - Asset Acquisition (Det

Note 4 - Asset Acquisition (Details Textual) - USD ($)	Mar. 31, 2022	Nov. 15, 2021	Sep. 30, 2021	Sep. 13, 2021	Aug. 31, 2022	Aug. 30, 2022	Jul. 31, 2023
Fortis Advisors Complaint [Member] | Forecast [Member]
Litigation Settlement, Amount Awarded to Other Party, Periodic Payment					$ 500,000	$ 500,000	$ 1,000,000
Subsequent Event [Member] | Fortis Advisors Complaint [Member]
Litigation Settlement, Amount Awarded to Other Party Immediately		$ 2,000,000
Litigation Settlement, Amount Awarded to Other Party		$ 17,000,000
FWB [Member]
Payments to Acquire Productive Assets, Total				$ 3,000,000
Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				624,025
Asset Acquisition, Consideration Transferred, Liabilities Incurred				$ 8,000,000
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable				$ 4,000,000
Shares Issued, Price Per Share (in dollars per share)				$ 6.41
FWB [Member] | Research and Development Expense [Member]
Asset Acquisition, Consideration Transferred, Non-contingent Consideration				$ 21,300,000
FWB [Member] | General and Administrative Expense [Member]
Asset Acquisition, Consideration Transferred, Transaction Cost				900,000
FWB [Member] | Development Achievement Threshold [Member]
Asset Acquisition, Potential Milestone Payments				$ 207,000,000
Asset Acquisition, Consideration Transferred, Contingent Consideration Percent				25.00%
Asset Acquisition, Consideration Transferred, Contingent Consideration			$ 0
FWB [Member] | Patent Infringement [Member]
Asset Acquisition, Consideration Transferred, Percent				10.00%
FWB [Member] | Subsequent Event [Member]
Asset Acquisition, Consideration Transferred, Liabilities Incurred	$ 7,000,000
Stock Cancelled During Period, Shares, Acquisitions (in shares)		332,913

Note 5 - Property, Equipment _3

Note 5 - Property, Equipment and Leasehold Improvements (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Total	$ 6,000	$ 8,000	$ 9,390	$ 26,556
Leasehold Improvements [Member]
Property, Plant and Equipment, Disposals			$ 29,000

Note 5 - Property, Equipment _4

Note 5 - Property, Equipment and Leasehold Improvements - Property, Equipment and Leasehold Improvements (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 87,817	$ 56,732
Less accumulated depreciation	(7,430)	(38,403)
Property, plant and equipment, net	80,387	18,329
Laboratory Equipment [Member]
Property, plant and equipment, gross	0	2,410
Computer Equipment [Member]
Property, plant and equipment, gross	11,540	19,676
Office Equipment [Member]
Property, plant and equipment, gross	48,277	5,483
Leasehold Improvements [Member]
Property, plant and equipment, gross	$ 28,000	$ 29,163

Note 6 - Intangible Assets an_3

Note 6 - Intangible Assets and Goodwill (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets, Net, Ending Balance	$ 2,483,875		$ 2,483,875		$ 2,879,536
Amortization of Intangible Assets, Total	132,000	$ 132,000	396,000	$ 396,000
Patents [Member]
Finite-Lived Intangible Assets, Net, Ending Balance	2,483,875		2,483,875		$ 2,879,536
Patents [Member] | Mayoly [Member]
Finite-Lived Intangible Assets, Net, Ending Balance	$ 3,800,000		$ 3,800,000

Note 6 - Intangible Assets an_4

Note 6 - Intangible Assets and Goodwill - Patents (Details) - Patents [Member] - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2020	Mar. 31, 2019
Patents	$ 3,802,745		$ 3,802,745
Mayoly [Member]
Patents	3,802,745			$ 1,740,959
Patents	$ 1,219,386	$ 449,280	$ 393,120

Note 6 - Intangible Assets an_5

Note 6 - Intangible Assets and Goodwill - Intangible Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Total	$ 2,483,875	$ 2,879,536
Patents [Member]
Patents	3,802,745	3,802,745
Less accumulated amortization	(1,318,870)	(923,209)
Total	$ 2,483,875	$ 2,879,536

Note 6 - Intangible Assets an_6

Note 6 - Intangible Assets and Goodwill - Amortization Expense (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
2021 (balance of year)	$ 131,887
2022	527,548
2023	527,548
2024	527,548
2025	527,548
2026	241,796
Total	$ 2,483,875	$ 2,879,536

Note 6 - Intangible Assets an_7

Note 6 - Intangible Assets and Goodwill - Goodwill (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Balance	$ 2,054,048	$ 1,886,686
Foreign currency translation	(109,306)	167,362
Balance	$ 1,944,742	$ 2,054,048

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses (Details Textual) $ in Millions	Sep. 30, 2021USD ($)
FWB [Member]
Asset Acquisition, Acquired Receivables	$ 15

Note 7 - Accounts Payable and_4

Note 7 - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Trade payables	$ 18,447,834	$ 1,558,591
Accrued expenses	135,072	127,012
Total accounts payable and accrued expenses	$ 18,582,906	$ 1,685,603

Note 8 - Note Payable (Details

Note 8 - Note Payable (Details Textual) - USD ($)	Nov. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Notes Payable, Current, Total		$ 0	$ 552,405
Financing Agreement for Directors and Officer's Liability Insurance [Member]
Debt Instrument, Term (Month)	9 months
Debt Instrument, Face Amount	$ 620,000
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Debt Instrument, Periodic Payment, Total	$ 70,000
Notes Payable, Current, Total		$ 0	$ 552,000

Note 9 - Convertible Debt (Deta

Note 9 - Convertible Debt (Details Textual) - USD ($)	Jan. 09, 2021	Jul. 16, 2020	Jan. 09, 2020	Feb. 14, 2019	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2020	Jun. 01, 2020	Jan. 02, 2020	Dec. 20, 2019
Note Warrants [Member]
Class of Warrant or Right, Exercise, Percentage of Common Stock Converted from Debt Instrument											50.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 10.70								$ 10.70
Warrants and Rights Outstanding, Term (Year)			5 years								5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			181,325
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise, Percentage of Common Stock Converted from Debt Instrument	7.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 9.60	$ 14.20							$ 12.10
Warrants and Rights Outstanding, Term (Year)	5 years	5 years	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	19,973		15,823				19,973	19,973		4,149
Placement Agent Warrants, Exercise Price 12.10 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 12.10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	4,149
Placement Agent Warrants, Exercise Price 14.20 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 14.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	15,823
ADEC Note 1 [Member]
Debt Instrument, Face Amount				$ 1,000,000
ADEC Notes [Member]
Proceeds from Issuance of Long-term Debt, Total				$ 2,000,000
Repayments of Long-term Debt, Total					$ 450,000	$ 1,550,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total					$ 104,000
Promissory Notes [Member]
Debt Instrument, Face Amount	$ 3,500,000
Proceeds from Issuance of Long-term Debt, Total			$ 3,500,000
Repayments of Long-term Debt, Total		$ 25,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 1,000
Debt Instrument, Maximum Principal Offering											$ 8,000,000
Debt Instrument, Interest Rate, Stated Percentage											9.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 9.70
Debt Instrument, Fee Amount			$ 277,000
Debt Instrument, Fee, Percentage of Principal			9.00%
Debt Instrument, Fee, Percentage of Gross Proceeds			1.00%
Debt Instrument, Fair Value Disclosure, Total	2,400,000
Debt Instrument, Convertible, Beneficial Conversion Feature	1,800,000
Debt Issuance Costs, Net, Total	500,000
Long-term Debt, Gross	$ 100,000
Interest Expense, Debt, Total							$ 400,000	$ 4,900,000
Amortization of Debt Discount (Premium)							120,000	1,500,000
Amortization of Beneficial Conversion Feature							193,000	2,300,000
Amortization of Debt Issuance Costs							63,000	800,000
Debt Instrument, Accrued Interest Expense							$ 27,000	$ 300,000
Promissory Notes [Member] | Edward J. Borkowski [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)									$ 10.70
Long-term Debt, Gross									$ 100,000

Note 10 - Other Liabilities - O

Note 10 - Other Liabilities - Other Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Lease liabilities	$ 94,794	$ 57,417
Other liabilities	71,497	0
Other Liabilities, Current, Total	166,291	57,417
Lease liabilities	295,689	19,123
Other Liabilities, Noncurrent, Total	$ 295,689	$ 19,123

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 13, 2021shares	Jul. 22, 2021USD ($)$ / sharesshares	May 26, 2021shares	Mar. 10, 2021USD ($)$ / sharesshares	Feb. 24, 2021USD ($)shares	Jan. 06, 2021USD ($)$ / sharesshares	Sep. 11, 2020shares	Jul. 16, 2020USD ($)$ / sharesshares	Nov. 01, 2019USD ($)shares	Jun. 09, 2021$ / sharesshares	Feb. 23, 2021$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Jun. 09, 2021$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Feb. 28, 2021shares	Jan. 05, 2021shares	Dec. 31, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares	Dec. 20, 2019$ / sharesshares	Feb. 24, 2019shares
Common Stock, Shares Authorized (in shares)	25,000,000												25,000,000			25,000,000		250,000,000		25,000,000	150,000,000	15,000,000	25,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001												$ 0.0001			$ 0.0001				$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized (in shares)	10,000,000												10,000,000			10,000,000						10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001												$ 0.0001			$ 0.0001						$ 0.0001
Stockholders' Equity Note, Stock Split, Conversion Ratio													10
Common Stock, Shares, Issued, Total (in shares)	11,115,228												11,115,228			11,115,228				3,115,031
Common Stock, Shares, Outstanding, Ending Balance (in shares)	11,115,228												11,115,228			11,115,228				3,115,031
Preferred Stock, Shares Issued, Total (in shares)	676.05												676.05			676.05
Preferred Stock, Remaining Authorized but Unissued (in shares)	9,919,805.19												9,919,805.19			9,919,805.19
Dividends Payable | $	$ 349,132												$ 349,132	$ 408,043		$ 349,132	$ 408,043
Stock Issued During Period, Value, New Issues | $													7,150,847			8,325,195	988,348
Stock Issued During Period, Value, Issued for Services | $													$ 123,549	22,500		$ 1,215,859	109,605
Stock Issued During Period, Shares, Acquisitions (in shares)													624,025
Stock Issued During Period, Shares, Treasury Stock Reissued (in shares)													332,913
Stock Issued During Period, Shares, Settlement (in shares)																7,500
Stock Issued During Period, Value, Settlement | $														85,770		$ 94,499	$ 85,770
Class of Warrant or Right, Exercised During Period (in shares)																952,588	0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 1,100,000												$ 1,100,000	2,200,000		$ 1,100,000	$ 2,200,000
Class of Warrant or Right, Issued During Period (in shares)																3,995,602	1,988,165
Deemed Dividends, Preferred Stock Issuances | $													$ 0	$ 8,155,212		$ 4,507,125	$ 8,155,212
Conversion of Stock, Warrants Issued (in shares)														5,977
Common Stock, Contingently Issuable (in shares)	1,633,720												1,633,720			1,633,720
Shares Contingently Issuable, Price Per Share (in dollars per share) | $ / shares	$ 3.40												$ 3.40			$ 3.40
Deemed Dividends, Preferred Stock Exchanges | $													$ 0	$ 0		$ 21,008,253	0
Proceeds from Issuance of Common Stock | $																$ 18,156,050	$ 988,348
Promissory Notes [Member]
Repayments of Long-term Debt, Total | $									$ 25,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total | $									1,000
Notes Payable, Total | $									$ 0
Class of Warrant or Rights, Investor and Pre_funded Warrants [Member]
Stock Issued During Period, Shares, Exercise of Warrants (in shares)																945,644
Class of Warrant or Right, Exercised During Period (in shares)																3,991,882
January 2021 Investor Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)																9,526,209
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 8						$ 8				$ 8		$ 8		$ 8	$ 8
Class of Warrant or Right, Issued During Period (in shares)							1,066,666
Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Contingently Issuable (in shares)	740,612												740,612			740,612
Exchange Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									177,293
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 8.50
Class of Warrant or Right, Issued, Percentage of Stock Issued Upon Conversion									25.00%
January 2021 Placement Agent Warrants [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares							$ 7.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							74,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 9.375
Equity Offering, Management Fee, Percentage of Gross Proceeds							1.00%
Placement Agent Fee and Management Fee | $							$ 700,000
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering							7.00%
Class of Warrant or Right, Exercise Price, Percentage of Equity Offering Price							125.00%
March 2021 Prefunded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					205,854
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.01
Equity Offering, Maximum Offering Shares (in shares)					580,000
The March 2021 Offering [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 12.725
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					392,927
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 12.10
Warrants and Rights Outstanding, Term (Year)					5 years
March 2021 Placement Agent Warrants [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 12.725
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					55,008
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 15.906
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering					7.00%
Class of Warrant or Right, Exercise Price, Percentage of Equity Offering Price					125.00%
Warrants and Rights Outstanding, Term (Year)					5 years
Wainwright Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 6.875
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering			7.00%
Class of Warrant or Right, Exercise Price, Percentage of Equity Offering Price			125.00%
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			73,181
Series C Preferred Stock Converted into Common Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares												$ 7.70
Conversion of Stock, Shares Issued (in shares)						33,699						1,316,662				3,125,460
Conversion of Stock, Shares Converted (in shares)						334.46						13,166.62				33,097.10
Conversion of Stock, Amount Converted | $						$ 2,000										$ 24,700,000
Conversion of Stock, Amount Converted, Accrued Dividends | $																$ 198,000
Series B Preferred Stock Converted into Common Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 7.70			$ 7.70
Conversion of Stock, Shares Issued (in shares)														34,127		258,278
Conversion of Stock, Shares Converted (in shares)														34.127448		258.08
Conversion of Stock, Amount Converted | $																$ 2
Conversion of Stock, Amount Converted, Accrued Dividends | $														$ 3,551		$ 3,000
Common Stock Dividends, Shares (in shares)														461
Series B Preferred Stock Converted into Series C Preferred Stock and Warrants [Member]
Conversion of Stock, Shares Issued (in shares)																19,140.14
Conversion of Stock, Amount Converted | $																$ 14,400,000
Preferred Stock, Issued, Convertible, Shares Issuable (in shares)																1,914,024
Conversion of Stock, Warrants Issued (in shares)											563,915				1,914,024	1,914,024
Conversion of Series C Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)																19,140.14
Conversion of Stock, Shares Converted (in shares)																1,839.76
Conversion of Stock, Warrants Issued (in shares)																1,914,014
Deemed Dividends, Preferred Stock Exchanges | $																$ 21,000,000
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)													20,200	3,164		97,230
Stock Issued During Period, Value, Issued for Services | $													$ 124,000	$ 25,000		$ 1,200,000
Consultants Or Outside Board [Member]
Stock Issued During Period, Shares, New Issues (in shares)														0
Consultants 2 [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)														13,284
Stock Issued During Period, Value, Issued for Services | $														$ 112,000
Outside Board [Member]
Stock Issued During Period, Shares, New Issues (in shares)																	10,593
Stock Issued During Period, Value, New Issues | $																	$ 131,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares														$ 12.40			$ 12.40
Exchange Investors [Member] | Promissory Notes Converted into Series B Preferred Stock and Warrants [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)									937
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)									468,499
Debt Conversion, Original Debt, Amount | $									$ 6,900,000
Debt Conversion, Original Debt, Amount, Accrued Interest | $									$ 300,000
Equity Line Agreement [Member] | Lincoln Park [Member]
Stock Issued During Period, Shares, New Issues (in shares)										48,716						0	149,519
Stock Purchase Agreement, Maximum Value of Committed Shares | $										$ 15,000,000
Stock Issued During Period, Value, New Issues | $										$ 297,000						$ 0	$ 988,000
Stock Purchase Agreement, Committed Shares, Remaining Value | $																$ 14,000,000
At The Market Offering Agreement [Member] | Wainwright [Member]
Stock Issued During Period, Shares, New Issues (in shares)													1,501,661			1,651,225
Stock Issued During Period, Value, New Issues | $													$ 7,400,000			$ 8,600,000
Stock Sales Agreement, Commission on Shares Sold, Percentage				3.00%
Stock Sales Agreement, Number of Shares Authorized (in shares)				50,000,000
Stock Issued During Period, Issuance Costs | $													$ 228,000			$ 274,000
Series B Purchase Agreement [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									1,456,282
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 8.50
Class of Warrant or Right, Issued, Percentage of Stock Issued Upon Conversion									50.00%
Class of Warrant or Right, Issued During Period (in shares)									987,783
Series B Private Placement [Member]
Proceeds from Issuance of Equity, Gross | $									$ 15,200,000
Proceeds from Issuance or Sale of Equity, Total | $									$ 13,200,000
January 2021 Offerings [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							1,066,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 8
Proceeds from Issuance of Equity, Gross | $							$ 8,000,000
Proceeds from Issuance or Sale of Equity, Total | $							$ 7,100,000
Equity Offerings, Placement Agent Cash Fee, Percentage of Gross Proceeds							8.00%
Non-accountable Expenses | $							$ 35,000
Legal Fees | $							125,000
Clearance Fees | $							12,900
Payments of Stock Issuance Costs | $							900,000
Deemed Dividends, Preferred Stock Issuances | $							4,300,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $							900,000
January 2021 Offerings [Member] | January 2021 Investor Warrants [Member]
Payments of Stock Issuance Costs | $							3,400,000
March 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					55,009
Proceeds from Issuance of Equity, Gross | $					$ 10,000,000
Proceeds from Issuance or Sale of Equity, Total | $					$ 9,100,000
Equity Offerings, Placement Agent Cash Fee, Percentage of Gross Proceeds					8.00%
Non-accountable Expenses | $					$ 35,000
Legal Fees | $					50,000
Clearance Fees | $					16,000
Placement Agent Fee | $					$ 800,000
Underwriting Agreement [Member] | Wainwright [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 5.50
Equity Offering, Maximum Offering Shares (in shares)			909,091
Non-accountable Expenses | $			$ 35,000
Legal Fees | $			125,000
Clearance Fees | $			15,950
Proceeds from Issuance of Common Stock | $			$ 5,100,000
Equity Offering, Underwriting Discount, Percentage of Gross Proceeds			8.00%
Over-Allotment Option [Member] | Wainwright [Member]
Stock Issued During Period, Shares, New Issues (in shares)			136,363
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)													0	174		0	1,008
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Grant Date, Fair Value | $														$ 6,000			$ 36,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)														0			400
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 394,000												$ 394,000	$ 394,000		$ 394,000	$ 394,000
Restricted Stock [Member] | First Commercial Sale of MS1819 [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	197,000												197,000	197,000		197,000	197,000
Restricted Stock [Member] | Vests Upon Total Market Capitalization Exceeding One Million [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 197,000												$ 197,000	$ 197,000		197,000	197,000
Share-based Compensation Arrangement by Share-based Payment Award, Unrecognized Costs, Vesting Milestone, Amount | $																$ 1	$ 1
The 2014 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	79,500
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	38,700												38,700			38,700
The 2014 Omnibus Equity Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	272,050												272,050			272,050
The 2020 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																175,246
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)								1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase								10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Shares, Available (in shares)																1,000,000
Stock Issued During Period, Shares, New Issues (in shares)																176,246
Share-based Compensation Arrangement by Share-based Payment Award, Shares, Available, Net of Issuance (in shares)																823,754
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)								1,500,000
July 2021 Offering [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)													1,045,454
March 2021 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)																1,625,454
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	5,194.81								5,194.805195				5,194.81			5,194.81				5,194.81
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001												$ 0.0001			$ 0.0001				$ 0.0001
Preferred Stock, Shares Issued, Total (in shares)	676.05												676.05			676.05				2,773.6
Preferred Stock, Remaining Authorized but Unissued (in shares)	2,168.14												2,168.14			2,168.14
Preferred Stock, Stated Value Per Share (in dollars per share) | $ / shares	$ 7,700												$ 7,700			$ 7,700
Preferred Stock, Dividend Rate, Percentage																9.00%
Preferred Stock, Dividends, Payment of Fractional Shares Amount | $																$ 100
Dividends Payable | $	$ 349,000												$ 349,000			349,000
Preferred Stock, Liquidation Preference, Value | $	$ 5,600,000												$ 5,600,000			$ 5,600,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 7.70												$ 7.70			$ 7.70
Preferred Stock, Convertible, Threshold Percentage of Stock Price Trigger																250.00%
Preferred Stock, Convertible, Stock Price Trigger (in dollars per share) | $ / shares																$ 19.25
Preferred Stock, Convertible, Threshold Consecutive Trading Days																20
Preferred Stock, Convertible, Exceeding Percentage of Affiliates																9.99%
Preferred Stock, Convertible, Exceeding Percentage Holder																19.99%
Conversion of Stock, Shares Converted (in shares)	1,839.76															676.05
Preferred Stock, Percentage of Stated Value, Repurchase Without Stockholder Approval								150.00%
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	676.05												676.05			676.05				2,773.6
Dividends, Preferred Stock, Total | $																$ 349,000
Series B Preferred Stock [Member] | Exchange Investors [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)									937,000
Series B Preferred Stock [Member] | Series B Purchase Agreement [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares									$ 0.0001
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares									$ 7.70
Stock Issued During Period, Value, New Issues | $									$ 2,912.583005
Shares Issued, Price Per Share (in dollars per share) | $ / shares									$ 7,700
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)									2,912,575
Series B Preferred Stock [Member] | Series B Private Placement [Member]
Stock Issued During Period, Value, New Issues | $									$ 1,975.58
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)									1,975,574
Series C Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	57,000												57,000			57,000			75,000	57,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001												$ 0.0001			$ 0.0001				$ 0.0001
Preferred Stock, Shares Issued, Total (in shares)	0												0			0				0
Preferred Stock, Remaining Authorized but Unissued (in shares)	41,902.90												41,902.90			41,902.90
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)												33,446
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0											334.46	0			0				0
Preferred Stock, Contingently Issuable (in shares)	7,406												7,406			7,406
Convertible Preferred Stock, Shares Issued Upon Conversion, Contingently Issuable (in shares)	740,612												740,612			740,612
Series C Preferred Stock [Member] | January 2021 Registered Direct Offering [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares																				$ 7.50
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																				533,333
Equity Offering, Maximum Offering Shares (in shares)																				5,333.333
Equity Offering, Price Per Share (in dollars per share) | $ / shares																				$ 750
Series C Preferred Stock [Member] | January 2021 Private Placement [Member]
Equity Offering, Maximum Offering Shares (in shares)																				5,333.3333
Series C Preferred Stock [Member] | January 2021 Offerings [Member]
Payments of Stock Issuance Costs | $							$ 4,600,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 6.87												$ 6.87	$ 8.50		$ 6.87	$ 8.50			$ 8.50	$ 10.70
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 66												$ 66	$ 73.70		$ 66	$ 73.70			$ 73.70	$ 73.70
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10														10
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)		1,706
Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						5
Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						10

Note 12 - Warrants (Details Tex

Note 12 - Warrants (Details Textual) - USD ($)	Mar. 10, 2021	Feb. 08, 2021	Jan. 06, 2021	Jul. 16, 2020	Jul. 14, 2020	Jan. 09, 2020	Feb. 24, 2021	Jun. 09, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 09, 2021	Sep. 30, 2021	Sep. 30, 2020	Jan. 09, 2021	Dec. 31, 2020	Jan. 02, 2020	Dec. 31, 2019	Dec. 20, 2019
Conversion of Stock, Warrants Issued (in shares)										5,977
Class of Warrant or Right, Issued During Period (in shares)												3,995,602	1,988,165
Class of Warrant or Right, Exercised During Period (in shares)												952,588	0
Proceeds from Warrant Exercises												$ 4,906,630	$ 0
Class of Warrant or Right, Issued in Period, Weighted Average Fair Value Per Share (in dollars per share)												$ 8.85	$ 8.80
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 6.87	$ 8.50		6.87	8.50		$ 8.50		$ 10.70
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)													32.50
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 66	73.70		$ 66	73.70		$ 73.70		$ 73.70
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)													73.70
Series B Preferred Stock Converted into Series C Preferred Stock and Warrants [Member]
Conversion of Stock, Warrants Issued (in shares)								563,915			1,914,024	1,914,024
Series C Preferred Stock Exchanged for Common Stock and Warrants [Member]
Conversion of Stock, Warrants Issued (in shares)												193,333
Common Stock Concerted into Series B Preferred Stock and Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 8.50			$ 8.50
Warrants and Rights Outstanding, Term (Year)										5 years			5 years
Class of Warrant or Right, Grant Date, Fair Value													$ 8,100,000
Conversion of Stock, Warrants Issued (in shares)													145,628
July 2021 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									73,181			73,181
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 6.875			$ 6.875
Warrants and Rights Outstanding, Term (Year)									5 years			5 years
Class of Warrant or Right, Grant Date, Fair Value									$ 263,000
January 2021 Investor Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 8					$ 8	$ 8		$ 8	$ 8
Class of Warrant or Right, Grant Date, Fair Value			$ 6,000,000				$ 21,000,000	$ 3,400,000
Class of Warrant or Right, Issued During Period (in shares)			1,066,666
Adjustments to Additional Paid in Capital, Warrant Issued			$ 3,400,000
Class of Warrant or Right, Prohibited Exercise (in shares)							1,350,108
Class of Warrant or Right, Exercised During Period (in shares)												9,526,209
Class of Warrant or Right, Pre-funded [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	205,854
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.10		$ 0.01
Class of Warrant or Right, Grant Date, Fair Value	$ 2,600,000		$ 1,600,000
January 2021 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			74,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 9.375
Class of Warrant or Right, Grant Date, Fair Value			$ 392,000
March 2021 Investor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	392,927
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 12.10
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Grant Date, Fair Value	$ 3,500,000
March 2021 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	55,008
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 15.906
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Grant Date, Fair Value	$ 453,000
Warrants to Consultant, Subject to Service-based Milestone Vesting Conditions [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 16.90
Warrants and Rights Outstanding, Term (Year)		4 years
Class of Warrant or Right, Grant Date, Fair Value		$ 214,000
Class of Warrant or Right, Vested During Period (in shares)									15,000			20,000
Share-based Payment Arrangement, Expense									$ 161,000			$ 214,000
January and March 2021 Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)												952,620
Stock Issued During Period, Shares, Exercise of Warrants (in shares)												945,633
Proceeds from Warrant Exercises												$ 4,900,000
Note Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						181,325
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 10.70												$ 10.70
Warrants and Rights Outstanding, Term (Year)						5 years												5 years
Class of Warrant or Right, Grant Date, Fair Value						$ 1,600,000
Class of Warrant or Right, Vesting Period (Year)						6 years
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						15,823				19,973			19,973	19,973		4,149
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 9.60		$ 14.20										$ 12.10
Warrants and Rights Outstanding, Term (Year)				5 years		5 years								5 years
Class of Warrant or Right, Grant Date, Fair Value				$ 745,000									$ 174,000
Conversion of Stock, Warrants Issued (in shares)				137,745
Exchange Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 8.50
Warrants and Rights Outstanding, Term (Year)				5 years
Class of Warrant or Right, Grant Date, Fair Value				$ 1,000,000
Conversion of Stock, Warrants Issued (in shares)				177,293
Warrants in Connection With Settlement With Former CEO [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 10
Warrants and Rights Outstanding, Term (Year)					5 years
Class of Warrant or Right, Grant Date, Fair Value					$ 85,000
Conversion of Stock, Warrants Issued (in shares)					15,000

Note 12 - Warrants - Warrant Tr

Note 12 - Warrants - Warrant Transactions (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Warrants outstanding and exercisable (in shares)	2,517,722	537,828
Granted during the period, warrants (in shares)	3,995,602	1,988,165
Expired during the period, warrants (in shares)	(51,061)	(5,977)
Exercised during the period, warrants (in shares)	(952,588)	0
Warrants outstanding and exercisable (in shares)	5,509,675	2,520,016
Minimum [Member]
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	$ 8.50	$ 10.70
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	0.01	8.50
Expired during the period, exercise price per share, warrants (in dollars per share)		32.50
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	6.87	8.50
Maximum [Member]
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	73.70	73.70
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	16.90	14.20
Expired during the period, exercise price per share, warrants (in dollars per share)		73.70
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	66	73.70
Weighted Average [Member]
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	12.20	25.30
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	7.77	8.80
Expired during the period, exercise price per share, warrants (in dollars per share)		51.50
Warrants outstanding and exercisable, exercise price per share (in dollars per share)	$ 9.96	$ 12.20

Note 12 - Warrants - Warrants E

Note 12 - Warrants - Warrants Exerciseable (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of warrants under share (in shares) | shares	5,509,675
Weighted average remaining contractual life (Year)	4 years 1 month 28 days
Weighted Average [Member]
Exercise Price (in dollars per share)	$ 9.96
Warrant One [Member]
Number of warrants under share (in shares) | shares	4,482,860
Weighted average remaining contractual life (Year)	4 years 4 months 24 days
Warrant One [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 0
Warrant One [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 9.99
Warrant Two [Member]
Number of warrants under share (in shares) | shares	840,745
Weighted average remaining contractual life (Year)	3 years 7 months 13 days
Warrant Two [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 10
Warrant Two [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 19.99
Warrant Three [Member]
Number of warrants under share (in shares) | shares	32,003
Weighted average remaining contractual life (Year)	1 year 9 months 25 days
Warrant Three [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 20
Warrant Three [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 29.99
Warrant Four [Member]
Number of warrants under share (in shares) | shares	61,155
Weighted average remaining contractual life (Year)	7 months 9 days
Warrant Four [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 30
Warrant Four [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 39.99
Warrant Five [Member]
Number of warrants under share (in shares) | shares	16,425
Weighted average remaining contractual life (Year)	6 months 10 days
Warrant Five [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 40
Warrant Five [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 49.99
Warrant Six [Member]
Number of warrants under share (in shares) | shares	72,714
Weighted average remaining contractual life (Year)	5 months 19 days
Warrant Six [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 50
Warrant Six [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 59.99
Warrant Seven [Member]
Number of warrants under share (in shares) | shares	3,773
Weighted average remaining contractual life (Year)	2 months 1 day
Warrant Seven [Member] | Minimum [Member]
Exercise Price (in dollars per share)	$ 60
Warrant Seven [Member] | Maximum [Member]
Exercise Price (in dollars per share)	$ 69.99

Note 12 - Warrants - Weighted A

Note 12 - Warrants - Weighted Average Assumptions (Details)	Sep. 30, 2021
Measurement Input, Expected Term [Member]
Assumption	5.19
Measurement Input, Price Volatility [Member] | Minimum [Member]
Assumption	0.838
Measurement Input, Price Volatility [Member] | Maximum [Member]
Assumption	0.908
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Assumption	0.0028
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Assumption	0.0167
Measurement Input, Expected Dividend Rate [Member]
Assumption	0

Note 13 - Stock Options (Detail

Note 13 - Stock Options (Details Textual) - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jan. 02, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 1,100,000		$ 2,200,000		$ 2,200,000	$ 1,100,000	$ 2,200,000		$ 1,100,000	$ 2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)										23,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)	167,524					167,524			167,524
Minimum [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)										$ 9.70
Maximum [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)										$ 36
The 2020 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)									$ 8.61
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)									175,246
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)									134,476
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									185,870
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)											274,065
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)						18,781			175,246
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share)						$ 102,000			$ 403,000
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member] | Minimum [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)						5.80			6.40
The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member] | Maximum [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)						$ 7.50			15.40
The 2014 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)				30,000			3,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)				$ 10.30			$ 8.50
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)							3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)										79,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share)				$ 23,000			$ 24,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)						0
Share-based Payment Arrangement, Expense							$ 25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)				633
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)				286
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount				$ 24,000
The 2014 Omnibus Equity Incentive Plan [Member] | Minimum [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)									8.50
The 2014 Omnibus Equity Incentive Plan [Member] | Maximum [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)									$ 36
Vesting Monthly [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 900,000		$ 1.2		1.2	$ 900,000	1.2		$ 900,000	$ 1.2
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 10 months 6 days		8 years 9 months
Completing Enrollment of Phase 2 OPTION 2 Clinical Trial [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 440,000		440,000		440,000			440,000
Public Announcement of Topline Data for Phase 2 OPTION 2 Clinical Trial [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			20,000		20,000		20,000			20,000
Completing Enrollment in Phase 2 Combination Trial in Europe [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			41,000		41,000		41,000			41,000
Initiating Phase 3 Trial in US [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 40,000		40,000		40,000	40,000	40,000		40,000	40,000
Public Release of Topline Data of Complete Combination Trial Results [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	140,000					140,000			140,000
Signing of Definitive Term Sheet with Board Approval [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	140,000					140,000			140,000
Initiating Phase 1 Trial for Product Other than MS1819 [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			40,000		40,000		40,000			40,000
Public Release of Topline Data [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			140,000		140,000		140,000			140,000
Comple Option 2 Trial Results [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			140,000		140,000		140,000			140,000
Signing Definitive Term Sheet [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 140,000		$ 140,000		$ 140,000			$ 140,000
New Sapirstein Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)								90,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)								$ 8.50
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 359,000					$ 359,000			$ 359,000
New Sapirstein Awards [Member] | Vesting Monthly [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		30,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)		18 months
New Sapirstein Awards [Member] | Vesting Immediately [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		20,000
New Sapirstein Awards [Member] | Milestone-based Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		40,000
New Schneiderman Awards Terms [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 8.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		28,500
New Schneiderman Awards Terms [Member] | Vesting Monthly [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		17,014
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)		25 months
New Schneiderman Awards Terms [Member] | Vesting Immediately [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		7,986
New Schneiderman Awards 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		3,500
New Schneiderman Awards 2 [Member] | Vesting Monthly [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		1,750
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)		19 months
New Schneiderman Awards 2 [Member] | Vesting Immediately [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		1,750
New Schneiderman Awards [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 192,000						$ 192,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)							204,000
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)							$ 8.50
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share)							$ 1,400,000
Share-based Payment Arrangement, Option [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)										33,500
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)										$ 10.30
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share)										$ 281,000
Share-based Payment Arrangement, Option [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)										46,000
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)										$ 9.70
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share)										$ 210,000
Share-based Payment Arrangement, Option [Member] | The 2020 Omnibus Equity Incentive Plan [Member] | Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)						3 years			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years			10 years
Excluding Prior Awards [Member] | The 2014 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)									15,477
Service-based Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)					23,425				41,614
Share-based Payment Arrangement, Expense					$ 139,000				$ 305,000
Service-based Vesting Options [Member] | General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense					120,000				245,000
Service-based Vesting Options [Member] | Research and Development Expense [Member]
Share-based Payment Arrangement, Expense					$ 20,000				$ 60,000
Performance-based Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									75,500	5,000
Share-based Payment Arrangement, Expense									$ 623,000	$ 20,000
Performance-based Vesting Options [Member] | General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense									253,000
Performance-based Vesting Options [Member] | Research and Development Expense [Member]
Share-based Payment Arrangement, Expense									$ 370,000
Performance-based Vesting Options [Member] | Completing Enrollment of Phase 2 OPTION 2 Clinical Trial [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									43,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									$ 427,000
Performance-based Vesting Options [Member] | Public Announcement of Topline Data for Phase 2 OPTION 2 Clinical Trial [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									21,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									$ 148,000
Performance-based Vesting Options [Member] | Completing Enrollment in Phase 2 Combination Trial in Europe [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									$ 8,000
Performance-based Vesting Options [Member] | Determining Initiating US Phase 1 Clinical Trial Probable [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									10,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									$ 40,000
Service-based Vesting Options 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)										60,008
Share-based Payment Arrangement, Expense										$ 361,000
Service-based Vesting Options 2 [Member] | General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense										341,000
Service-based Vesting Options 2 [Member] | Research and Development Expense [Member]
Share-based Payment Arrangement, Expense										$ 20,000

Note 13 - Stock Options - Weigh

Note 13 - Stock Options - Weighted-average Assumptions (Details)	9 Months Ended
	Sep. 30, 2021
Contractual term (in years) (Year)	10 years
Volatility, minimum	83.80%
Volatility, maximum	90.60%
Risk-free interest rate, minimum	83.90%
Risk-free interest rate, maximum	1.69%

Note 13 - Stock Options - Stock

Note 13 - Stock Options - Stock Option Activity (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Canceled during the period (in shares) | shares		(23,500)
Non-vested stock options outstanding remaining contractual life (Year)	8 years 10 months 13 days
Non-vested stock options outstanding, intrinsic value | $	$ 0
Non-vested stock options outstanding (in shares) | shares	167,524
Non-vested stock options outstanding, average exercise price (in dollars per share)	$ 8.44
The 2014 and 2020 Omnibus Equity Incentive Plan [Member]
Stock options outstanding (in shares) | shares		167,750	167,750
Stock options outstanding, average exercise price (in dollars per share)		$ 21.70	$ 21.70
Stock options outstanding, remaining contractual life (Year)		6 years 6 months 7 days		5 years 4 months 13 days
Stock options outstanding, intrinsic value | $		$ 0		$ 0
Granted during the period (in shares) | shares		287,001
Granted during the period, average exercise price (in dollars per share)		$ 8.90
Granted during the period remaining contractual life (Year)		9 years 9 months 14 days
Granted nonvested options during the period remaining contractual life (Year)		10 years
Canceled during the period (in shares) | shares		(23,500)
Canceled during the period, average exercise price (in dollars per share)		$ 19.40
Canceled during the period remaining contractual life (Year)		3 years 3 months 10 days
Stock options outstanding (in shares) | shares		431,251		167,750
Stock options outstanding, average exercise price (in dollars per share)		$ 13.80		$ 21.70
Exercisable (in shares) | shares		131,275
Exercisable, average exercise price (in dollars per share)		$ 22.20
Exercisable remaining contractual life (Year)		6 years 1 month 2 days
Exercisable, intrinsic value | $		$ 0
Non-vested stock options outstanding (in shares) | shares		88,350	88,350
Non-vested stock options outstanding, average exercise price (in dollars per share)		$ 13.30	$ 13.30
Non-vested stock options outstanding remaining contractual life (Year)		8 years 9 months		6 years 3 months 3 days
Non-vested stock options outstanding, intrinsic value | $		$ 0		$ 0
Granted during the period, average exercise price (in dollars per share)		$ 10
Vested during the period (in shares) | shares		(59,375)
Vested during the period, average exercise price (in dollars per share)		$ 25.90
Vested during the period remaining contractual life (Year)		6 years 10 months 17 days
Canceled during the period (in shares) | shares		(16,000)
Canceled during the period, average exercise price (in dollars per share)		$ 13
Canceled during the period remaining contractual life (Year)		7 years 1 month 6 days
Non-vested stock options outstanding (in shares) | shares		299,976		88,350
Non-vested stock options outstanding, average exercise price (in dollars per share)		$ 9.80		$ 13.30
The 2020 Omnibus Equity Incentive Plan [Member]
Stock options outstanding (in shares) | shares	407,026
Stock options outstanding, average exercise price (in dollars per share)	$ 12.46
Stock options outstanding, remaining contractual life (Year)	7 years 6 months 25 days		7 years 11 months 8 days
Stock options outstanding, intrinsic value | $	$ 0		$ 0
Granted during the period (in shares) | shares	175,246
Granted during the period, average exercise price (in dollars per share)	$ 8.61
Granted during the period remaining contractual life (Year)	10 years
Canceled during the period (in shares) | shares	(134,476)
Canceled during the period, average exercise price (in dollars per share)	$ 10.47
Canceled during the period remaining contractual life (Year)	2 years 10 months 13 days
Stock options outstanding (in shares) | shares	447,796		407,026
Stock options outstanding, average exercise price (in dollars per share)	$ 11.55		$ 12.46
Exercisable (in shares) | shares	280,272
Exercisable, average exercise price (in dollars per share)	$ 13.76
Exercisable remaining contractual life (Year)	6 years 9 months 10 days
Exercisable, intrinsic value | $	$ 0
Non-vested stock options outstanding (in shares) | shares	274,065
Non-vested stock options outstanding, average exercise price (in dollars per share)	$ 9.90
Non-vested stock options outstanding remaining contractual life (Year)			8 years 5 months 1 day
Non-vested stock options outstanding, intrinsic value | $			$ 0
Granted during the period, average exercise price (in dollars per share)	$ 8.61
Vested during the period (in shares) | shares	(185,870)
Vested during the period, average exercise price (in dollars per share)	$ 10.38
Canceled during the period (in shares) | shares	(95,917)
Canceled during the period, average exercise price (in dollars per share)	$ 0
Non-vested stock options outstanding (in shares) | shares			274,065
Non-vested stock options outstanding, average exercise price (in dollars per share)			$ 9.90

Note 14 - Agreements (Details T

Note 14 - Agreements (Details Textual) - USD ($)	Feb. 24, 2021	Jan. 08, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Feb. 23, 2021	Dec. 31, 2020	Dec. 30, 2020
Research and Development Expense, Total			$ 24,378,318	$ 1,795,684	$ 32,542,143	$ 4,438,229
Stock Issued During Period, Value, New Issues			7,150,847		8,325,195	988,348
Deemed Dividends, Preferred Stock Issuances			0	8,155,212	4,507,125	8,155,212
Fair Value, Option, Changes in Fair Value, Gain (Loss)			$ 0	$ 0	532,353	$ 0
Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							33,446
Series C Preferred Stock [Member] | First Wave Purchase Agreement [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)		$ 7.50
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)		329,019
Stock Issued During Period, Shares, New Issues (in shares)		3,290.1960
Stock Issued During Period, Value, New Issues		$ 2,500,000
Deemed Dividends, Preferred Stock Issuances		230,000
First Wave License Agreement [Member]
Asset Acquisition, Cash to be Paid in First Ten Days								$ 9,000,000
Asset Acquisition, Additional Cash to be Paid								1,250,000
Asset Acquisition, Contingent Consideration, Liability, Total								$ 37,000,000
Research and Development Expense, Total					1,000,000
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable					3,000,000
Fair Value, Option, Changes in Fair Value, Gain (Loss)	$ 500,000
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value									$ 3,000,000
Redeemable Noncontrolling Interest, Equity, Common, Fair Value		$ 2,500,000
First Wave License Agreement [Member] | Convertible Preferred Stock [Member]
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable					$ 3,000,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 9.118		$ 9.118
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)			329,019		329,019

Note 15 - Leases (Details Textu

Note 15 - Leases (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Jun. 01, 2021ft²
Operating Lease, Expense | $	$ 79,000	$ 55,000	$ 186,000	$ 129,000
Office Space at 777 Yamato Road, Suite 502, Boca Raton, FL 33431 [Member]
Lessee, Operating Lease, Term of Contract (Month)					63 months
Area of Real Estate Property (Square Foot) | ft²					3,472

Note 15 - Leases - Weighted-ave

Note 15 - Leases - Weighted-average Remaining Lease Term and Weighted-average Discount Rate Under Operating Leases (Details)	Sep. 30, 2021
Weighted-average remaining lease term (years) (Year)	4 years 6 months
Weighted-average discount rate	6.91%

Note 15 - Leases - Maturities o

Note 15 - Leases - Maturities of Operating Lease Liabilities (Details)	Sep. 30, 2021USD ($)
2021	$ 57,019
2022	81,254
2023	83,691
2024	86,202
2025	88,788
Thereafter	60,593
Total lease payments	457,547
Less imputed interest	(67,064)
Present value of lease liabilities	$ 390,483

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Tax Expense (Benefit), Total	$ 0	$ 0
Unrecognized Tax Benefits, Ending Balance	$ 0		$ 0

Note 17 - Net Loss Per Common_2

Note 17 - Net Loss Per Common Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Common Stock and Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	721,364	2,931,440
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	5,509,675	736,118
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	11,200
Restricted Stock and Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	27,500	38,700
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	448,296	227,250
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		2,931,440
Outstanding Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		2,520,016
Uneared and Unissued Restricted Stock and RSU 2 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		38,700
Outstanding Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		431,250

Note 18 - Employee Benefit Pl_2

Note 18 - Employee Benefit Plans (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage			6.00%
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 26,000	$ 40,000	$ 81,000	$ 62,000
Minimum [Member]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			1.00%
Maximum [Member]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			100.00%

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) - USD ($)	Nov. 15, 2021	Oct. 29, 2021	Oct. 04, 2021	Nov. 14, 2021	Aug. 31, 2022	Aug. 30, 2022	Jul. 31, 2023
Fortis Advisors Complaint [Member] | Forecast [Member]
Litigation Settlement, Amount Awarded to Other Party, Periodic Payment					$ 500,000	$ 500,000	$ 1,000,000
Subsequent Event [Member] | Fortis Advisors Complaint [Member]
Loss Contingency, Damages Sought, Value		$ 8,000,000
Litigation Settlement, Amount Awarded to Other Party Immediately	$ 2,000,000
Litigation Settlement, Amount Awarded to Other Party	$ 17,000,000
Subsequent Event [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				13.80
Conversion of Stock, Amount Converted				$ 113,900
Conversion of Stock, Shares Issued (in shares)				33,500
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 3.40
Subsequent Event [Member] | Milestone For Clinical Development [Member]
Payment for Contingent Consideration Liability, Operating Activities			$ 2,000,000